
# **National Drug Driving Study**

February 2023



Prepared By: Road Safety & Public Health Research Team at Department of Emergency Medicine, University of British Columbia





THE UNIVERSITY OF BRITISH COLUMBIA





THE UNIVERSITY OF BRITISH COLUMBIA

# **National Drug Driving Study**

Prepared by: Road Safety & Public Health Research Team, Department of Emergency Medicine, University of British Columbia

This study has been made possible through funding from Health Canada, the Canadian Institutes of Health Research, the Canadian Centre on Substance Use and Addiction, Ministry of Transportation Ontario, Saskatchewan Government Insurance and Alberta Transportation. The views expressed herein do not necessarily represent the views of the funders.

<u>Suggested Citation</u>: Brubacher JR, Chan H, Erdelyi S, Simmons S, Sergei Likhodi and the National Drug Driving Research Group. The 2021 National Drug Driving Study. Vancouver, BC. Department of Emergency Medicine, University of British Columbia.

Contributions of the following individuals have made this project possible and successful across Canada. Thank you, for your hard work.

Canadian Drug Driving Study Research Group:

Dr. Paul Atkinson	Dalhousie University (Dalhousie Medicine New Brunswick)
Dr. Floyd Besserer	University of Northern British Columbia
Dr. Jeff Brubacher	University of British Columbia
Dr. Herbert Chan	University of British Columbia
Dr. David Clarke	Dalhousie University
Dr. Raoul Daoust	University of Montreal
Dr. Phil Davis	University of Saskatchewan
Dr. Jeff Eppler	University of British Columbia
Dr. Marcel Emond	Université Laval
Dr. Chrystal Horwood	Memorial University
Dr. Jacques Lee	University of Toronto
Dr. Andrew MacPherson	University of British Columbia
Dr. Kirk Magee	Dalhousie University
Dr. Éric Mercier	Université Laval
Dr. Robert Ohle	Health Sciences North Research Institute
Dr. Michael Parsons	Memorial University
Dr. Jagadish Rao	University of Saskatchewan
Dr. Brian Rowe	University of Alberta
Dr. John Taylor	University of British Columbia
Dr. Christian Vaillancourt	University of Ottawa
Dr. Ian Wishart	University of Calgary

Site Research Coordinators and Assistants:

Faiyzah Ahmed, Durr Al-Hakim, Gabi Andrus, Lorelei Audas, Alexandra Beaudin, Manya Charette, Mackenzie Cheyne, Amélie Côté-Lévesque, Stephanie Couperthwaite, Christina Cherian, Yannick Cyr-Lemoignan, Samuel Gagnon, Ashlee de Medeiros, Corinne DeMone, Frédérique Bahary-Dionne, Madison Donoghue, Carly Ethier, Jacqueline Fraser, Fabien Henri, Taylor Karn, Nelofar Kureshi, Chantal Lanthier, Emilie Lapointe, Meagan Larson, Anam Liaqat, Jianing Lv, Dominic Martel, Megan Martin, Pamela McDougall, Dr. Alexandra Nadeau, Elodie Ouellet-Belleau, Asadullah Panawala, Dawn Parker, Amanda Pearce, Lydia Redjah, Tracy Peatt, Lulu Pei, Sudaba Popal, Lydia Redjah, Natalie Runham, Catherine St George, Andrea Stringer, Amanda Swirhun, Danielle Waltenbury, Taylor Weir, Joanna Yeung, Gabriele Zitikyte



### **Table of Contents**

Terminology and Definitions	4
Background	7
Methods	9
Results	11
Discussion	12
Summary	13
Appendix A: Tables	14
Appendix B: Figures	43
References	73



### **Terminology and Definitions**

### **Cannabinoids**

Marijuana contains over 60 active compounds known as cannabinoids. When absorbed into the blood, cannabinoids exert their effects by binding to receptors in the brain and throughout the body.

### THC (delta-9-tetrahydrocannabinol)

THC is the main psycho-active compound found in marijuana and is responsible for most of marijuana's impairing effects.

### THC Levels

The term "THC level" refers to the amount of THC within a person's body after smoking, vaporizing or eating a cannabis product. There are different ways to measure THC levels. The best way to understand if someone has used cannabis recently is to look at the THC level in their blood. However, interpreting the precise time that someone took cannabis – and importantly, whether or not they are still experiencing its effects – is complicated. Immediately after smoking a "joint", whole blood THC levels typically peak at >100 ng/mL within 15 minutes and then drop rapidly so that, in occasional users, THC is usually <2ng/mL (i.e., the legislated limit associated with a summary offence in Canada) within 4 hours after a single acute exposure.<sup>1</sup> However, in habitual marijuana users, THC accumulates in body fat and is then slowly released back into the blood. As a result, habitual users can have THC levels in the range of 1 -3 ng/mL for days or even weeks after last use.<sup>2</sup> In most cases, however, THC > 5 ng/mL (i.e., the legislated limit associated with a hybrid offence in Canada) indicates recent use. After smoking a marijuana joint, the psychotropic (impairing) effects typically peak at 20–30 minutes and resolve by 4 hours. Ingesting cannabis delays the onset and extends the duration of effect.

### COOH-THC (11-nor-9-carboxy-delta-9-tetrahydrocannabinol)

The main metabolite (breakdown product) of THC. COOH-THC does not cause impairment and persists in blood and urine long after impairment has resolved. Thus COOH-THC provides evidence of previous cannabis exposure but does not necessarily indicate impairment or recent use.

### **Polysubstance Use**

People who use drugs often take more than one substance at the same time. This is referred to as polysubstance use. Taking several drugs in combination can lead to worse impairment than would be seen from either substance taken alone.

### Liquid chromatography/tandem mass spectrometry (LC-MS/MS)

An advanced laboratory technology that is used to detect and/or quantify a wide range of drugs using standards of known substances and concentrations.

### **Gas Chromatography-Flame Ionization Detection**

A standard laboratory technique used for measuring blood alcohol levels.

### **Phlebotomists**

Specially trained technicians who obtain blood samples from patients.



### Drug-impaired driving vs. drug-driving

"Drug-impaired driving" means that the driver is impaired by drugs, where "impaired" means that those drugs interfere with safe driving ability. When drivers have positive tests for drugs, we often do not know if they were actually engaging in "drug-impaired driving." This is because the presence of drugs in body fluids indicates prior drug use but not necessarily impairment. When drugs are detected within a driver's body fluids, but we do not know whether that driver was actually impaired at the time of testing, we use the term "drug driving."

### **Central Nervous System Depressants**

Many prescription medications cause sedation either as a desired therapeutic effect or as an unwanted side effect. In the Drug Evaluation and Classification System, these drugs would be classified as CNS (central nervous system) depressants. Common sedating medications include:

### Benzodiazepines

These are mild sedatives most commonly prescribed as "sleeping pills" or to treat anxiety.

### Anticonvulsants

Anticonvulsants, more commonly known as antiepileptic drugs, may cause sedation, dizziness, and cognitive changes.

### **Antihistamines**

Antihistamines cause sedation as an unwanted side effect. Over the counter antihistamines are used to treat allergies (e.g. diphenhydramine - "Benadryl"), or motion sickness (e.g. dimenhydrinate - "Gravol").

### Antidepressants

Antidepressants, especially the older antidepressants, have sedation as a side effect.

### **Antipsychotics**

Sedation is a common side effect of antipsychotic drugs.

#### Muscle relaxants

Muscle relaxants may have sedative effects such as drowsiness. People are generally advised not to drive or operate heavy machines while under the effects of muscle relaxants.

### Non-benzodiazepine hypnotics

Also known as "Z-drugs". These drugs are sedatives that act like benzodiazepines and are prescribed mostly as sleep aids. In Canada the most common non-benzodiazepine hypnotic is zopiclone.

### **Opioids**

Opioids are narcotic analgesics (pain killers) that can cause marked sedation or even coma along with respiratory depression. Opioids include prescription medications such as codeine, hydromorphone, oxycodone, and morphine. The street drug heroin is also an opioid.

### **Central Nervous System Stimulants**

CNS stimulants are drugs, such as cocaine or amphetamines, that cause CNS stimulation. Intoxication with these drugs is characterized by restlessness or agitation, pressured speech, anxiety, paranoia and



aggressive behaviour. Judgement may be impaired. Blood pressure and pulse are increased and pupils are dilated.

### **Psychomotor Skills**

Safe driving involves the application of a number of psychomotor skills. These refer to the skills we use to perceive sensory information, interpret its meaning, and respond through physical actions." Examples of psychomotor skills applied to driving include reaction time, tracking ability (e.g. ability to drive a car in a straight line without weaving), coordination, and tasks that require attention.



### Background

The epidemiology and risk of crashing in drinking drivers is well understood as a result of intense research conducted over the past 50 years.<sup>3-6</sup> This knowledge has facilitated the development of effective measures targeting alcohol-impaired driving. Alcohol-impaired driving and related fatalities are declining as a result of visibly enforced laws, administrative licensing sanctions, and social marketing campaigns.<sup>7-</sup> <sup>11</sup> Drug driving is also viewed as a major threat to road safety,<sup>12</sup> and the prevalence of drug driving may be increasing.<sup>13</sup> In fact, there is evidence that *drug driving has become as common as driving after drinking alcohol in Canada*.<sup>14-18</sup> With cannabis legalization, there is concern that the prevalence of drug driving, especially driving after using cannabis, will increase. Cannabis legalization could also result in more drivers combining cannabis with alcohol or other drugs, resulting in additive impairment.<sup>19-21</sup>

The effect of alcohol on driving and road safety is well-studied and understood. Experimental and epidemiological studies have made it possible to predict how driving will be affected at different breath and blood alcohol concentrations. For example, the risk of crashing approximately doubled at a BAC between 0.05% and 0.08%.<sup>6</sup> However, drugs tend to have more complicated pharmacokinetics and pharmacodynamics than alcohol. Unlike alcohol, it is often not possible to predict how driving will be affected at different drug blood alcohol concentrations. This issue makes it difficult to differentiate drugdriving (i.e., positive for drugs but absence of impairment) from drug-impaired driving (i.e., positive for drugs and active impairment) in epidemiological studies, and it makes it difficult to extrapolate the results of experimental studies focused on drug-impaired driving to real world safety. For example, we know that many drugs impair the psychomotor skills and/or judgment required for safe driving. Cannabis intoxication causes attention deficits, slows reaction time and impairs tasks such as tracking ability (e.g., staying within a lane) or monitoring the speedometer.<sup>19, 22-26</sup> Several expert panels compared experimental studies of impairment from THC with that from alcohol, in both males and females, and concluded that a blood alcohol concentration (BAC) of 0.05% causes a similar degree of psychomotor impairment as THC levels in whole blood of 2-5ng/mL.<sup>27-29</sup> However, habitual cannabis users may develop tolerance to some of the impairing effects of cannabis. <sup>30-32</sup> Differences in tolerance between users calls into question the ability to reliably infer impairment for any given user based on a specific THC level. In particular, a conservative THC limit imposed on all drivers may be inequitable for habitual users, who may be more likely to have cannabis in their system at any given time, yet less likely to experience impairment at that THC level. Additionally, although cannabis-impaired driving is very topical, it is important to realize that many other drugs also cause psychomotor skill impairment. Stimulants, such as cocaine and amphetamines, impair judgment, impair inhibitory control (ability to "tune out" and not react to irrelevant stimuli), and alter mood.<sup>33-40</sup> Sedating medications, such as benzodiazepines, antihistamines, antidepressants, Z-drugs (non-benzodiazepine sedatives such as zopiclone), and opioids, cause drowsiness, slow reaction time, impair cognitive function and impair tracking ability.<sup>41-51</sup> For these reasons, many drugs are suspected to increase the risk of crashing. Several recent meta-analyses all concluded that cannabis increases the risk of crashing, albeit to a lesser extent than alcohol.<sup>52-55</sup> There is epidemiological evidence that other drugs (amphetamines, cocaine, benzodiazepines, antihistamines, antidepressants and opioids) also increase crash risk. In fact, the crash risk with many of these drugs, although lower than that with alcohol, appears to be as high as or even higher than the risk associated with cannabis.55-58

The prevalence of drug driving in Canada is poorly studied. Previous research on the prevalence of drug use in Canadian drivers is based on roadside surveys, coroner's reports, police crash reports, or self-



reported surveys.<sup>14, 16, 59-61</sup> These methods have significant limitations. In roadside surveys, police pull over drivers and direct them to a safe parking spot. Researchers then ask the drivers about drug and alcohol use and obtain samples for drug testing. Roadside surveys are limited by high refusal rates which could result in selection bias if drivers who used drugs are more likely to refuse than other drivers. For practical reasons, roadside surveys use saliva rather than blood. However, blood THC levels are considered more informative than saliva THC levels because THC crosses freely from the blood into the brain,<sup>62</sup> whereas saliva THC represents deposition of THC in the mouth during smoking and is poorly correlated with blood THC concentrations.<sup>63</sup> For logistic reasons, roadside surveys typically sample a large number of drivers over a few days during the summer (when weather is good) making these surveys poorly suited for long term monitoring of drug driving. Another limitation is that, because of high cost and logistic challenges, roadside surveys are seldom performed. Coroner's data provide another estimate of the prevalence of drug use in drivers. In 2016, 82.7% of fatally injured Canadian drivers were tested for drugs and 46.7% were positive for an impairing drug other than alcohol, including 23.1% who tested positive for cannabis. Females were less likely than males to be positive for alcohol but almost as likely to test positive for drugs (41.7% in females versus 48.2% in males).<sup>64</sup> Coroner's data are useful but can be susceptible to selection bias if drug testing is based on suspicion of drug use and not performed routinely on all drivers. In Canada, the percentage of fatally injured drivers tested for drugs (2008) varies by province, ranging from 10% to 100%. The toxicology testing protocols used by coroners differ from province to province - with different protocols detecting different drugs. Coroner's data often fail to between distinguish between drug exposure that last occurred within the hours, days or weeks prior to the crash because some coroners measure inactive drug metabolites (which can persist in the body for long periods) rather than active drug. If fatally injured drivers survive the crash for a period of time, drug levels will decline with metabolism, making toxicology testing unreliable. Interpreting drug levels from coroner's data is further complicated by postmortem redistribution. For some drugs (such as cannabis), postmortem redistribution of drug concentrations within the body can lead to significant differences between the measurable drug level immediately prior to death (which is more representative of the actual drug level at the time of the crash) and the drug level measurable some time later after death.<sup>65-69</sup> As driving while impaired by drugs is illegal, *police crash reports* allow police to record their suspicion that a driver is impaired by drugs. However, these reports provide unreliable estimates of cannabis/other drug use as police only identify a small fraction of drivers who use cannabis or other drugs.<sup>70</sup> Self-report surveys ask questions about driving after using cannabis or other drugs.<sup>71</sup> Surveys are subject to selection, recall and reporting biases. In addition, self-report surveys typically lack precision because they ask about drug use before driving in a given time period (e.g., previous month) instead of before a specific driving episode.

This is a national drug driving project that studies drug use in injured drivers who present to hospital and have bloodwork obtained within six hours of a motor vehicle collision. To address the limitations of prior research, we study a relevant population (injured drivers) and measure a wide range of impairing drugs in blood within six hours of a crash. Hence, this research has several advantages over other methods of studying drug driving. We aim to provide relevant data that policy makers and injury prevention groups can use to inform policy and programs designed to prevent people from driving after using drugs.

The study is ongoing, and this report covers national data collected up to August 2022. Additional blood samples from 2022 will be analyzed and included in future reports. Note that data collection for this study began in Vancouver, British Columbia in April 2008. Starting in January 2018 research has expanded to include trauma centres from outside British Columbia. Only data from 2018 onward are included in this report.



### **Methods**

### **Inclusion and Exclusion Criteria**

We include all moderately or severely injured drivers of motorized vehicles (e.g. cars, motorcycles, trucks) who visited the emergency department (ED) of a participating hospital between 2018 and 2022 and had blood samples obtained within 6 hours of the crash. As of February 2023, 17 hospital sites have obtained research ethics and operational approval and are participating in this study. Fifteen of these hospitals contributed to this report, data from the other two hospitals has not yet been analyzed. These trauma centres are located in BC, Alberta, Saskatchewan, Ontario, Quebec, New Brunswick, Nova Scotia and Newfoundland. Injury severity is defined pragmatically as the need to obtain blood for clinical purposes (moderate injury), or need for overnight hospital admission (severe injury). Potentially eligible drivers are identified by daily review of ED visit logs and eligibility is confirmed through chart review. We exclude drivers with minor injuries who do not require blood testing for clinical purposes, drivers under 16 years of age, cases in which blood was first obtained more than 6 hours after the crash, cases in which no excess blood remains after clinical use, and cases in which the quantity of excess blood was insufficient for toxicology testing of all substances.

### **Chart Review**

ED records of eligible drivers are reviewed, and relevant data is abstracted and entered in REDCap, a secure web application for building and managing online surveys and databases. ED records include ambulance records (filled by paramedics), emergency physician notes, nursing notes, laboratory results including blood alcohol concentration (BAC), and consultant notes (if applicable). The abstracted data includes age, sex, first three digits of postal code, crash time and date, crash type (single vs multiple), vehicle type, blood draw time, prescription medications used in last 30 days, medical history, documentation of alcohol or drug use, disposition and medications given as part of clinical care prior to blood draw (we exclude "post-crash" medications when reporting toxicology results).

### **Blood Handling**

Blood availability is determined by research assistants through review of medical records (to identify drivers who had blood samples drawn) followed by a visit to the hospital laboratory to see if excess blood remains. Excess blood is relabeled with study ID number replacing the clinical label and frozen at -40° C for future analysis. Freezing is important as significant losses of THC/other drugs will occur by two months if blood is stored at room temperature. As blood concentrations of certain drugs, such as cocaine and THC, drop rapidly after use, it is important that time from crash until blood draw is carefully recorded. The time of crash is determined through chart reviews (usually recorded on the ambulance record), and phlebotomists record the time of blood draw. Blood samples are stored in a specimen freezer at each site before shipment on dry ice by overnight courier to the central laboratory in Vancouver where samples are stored at -40° C until ready for analysis.

### **Toxicology Analysis**

In participating hospitals, blood from injured drivers is usually tested for alcohol as part of routine trauma care. When clinical alcohol levels were not available, alcohol was measured at the Provincial Toxicology Centre using Gas Chromatography-Flame Ionization Detection with a detection limit of 0.01%. In addition, broad spectrum drug screens were performed on each patient's blood using liquid chromatography/tandem mass spectrometry (LC-MS/MS). The extraction process recovers both acidic



and basic drugs and is able to detect illicit drugs and their metabolites (cannabinoids, cocaine, amphetamines including their major analogues, and opioids) as well as psychotropic pharmaceuticals (including antihistamines, benzodiazepines, other hypnotics, and sedating antidepressants). The method has detection limits of 0.2 ng/mL for THC and 1 ng/mL for most other substances. When samples are positive for cannabinoids, we quantify both the active ingredient (THC) and the metabolite (COOH-THC). For other drugs, the LC-MS/MS screen will provide a quantitative measure of drug concentration using ISO-certified reference calibrators. Over 95% of excess blood samples in this study consisted of whole blood. When plasma is available but whole blood was not, we adjust plasma toxicology results to equivalent whole blood results according to previously published studies.



### Results

Between January 2018 and February 2023, we screened over 24,460 injured ED motorists including approximately 22,130 drivers (about 400 off road vehicle drivers) and 2,330 passengers. Of the 22,130 drivers, about 10,500 drivers met the inclusion criteria with blood samples collected. This report includes data from 8317 drivers who were injured between January 2018 and August 2022 with complete chart review and toxicology analysis in British Columbia, Alberta, Saskatchewan, Ontario, Quebec, New Brunswick, Nova Scotia and Newfoundland. Toxicology results from the remaining drivers (approximately 2,200) are not yet available. Findings from passengers and off-road vehicle drivers are not included in this report.

Overall, 17.9% of drivers in this sample tested positive for THC (including 7.8% with THC  $\geq$  2 ng/mL and 3.5% with THC  $\geq$  5 ng/mL). We also found that 16.1% of drivers tested positive for alcohol including 12.3% with BAC  $\geq$  0.08%. Opiates were detected in 11% of drivers, CNS stimulants (cocaine, amphetamines) in 11.8%, and CNS depressants in 26.5% of injured drivers.

These results, broken down by age, sex and by crash characteristics are shown in Tables 1 and 2 in Appendix A and in Figures 1 to 15 in Appendix B. For comparison purposes, Table 3 in Appendix A and Figure 18 in Appendix B summarize results from all participating hospitals in British Columbia, Alberta, Saskatchewan, Ontario, Quebec, and the Atlantic provinces (Nova Scotia, New Brunswick and Newfoundland). Sites in Atlantic provinces started recruitment in 2019 and had relatively lower volume, therefore their results are aggregated together until a bigger sample size is reached in those provinces. Results between provinces cannot be directly compared without adjusting for age, sex, injury severity and type of crash (singe versus multi-vehicle). Within these limitations, it appears that injured drivers from the Atlantic provinces and Saskatchewan are more likely to have consumed cannabis and are more likely to have been drinking.

Table 4 in Appendix A and Figures 16 and 17 in Appendix B show polysubstance use, the percentage of drivers who used various combinations of alcohol and cannabis (Figure 16) or other drug combinations (Figure 17). Figures 19 - 27 in Appendix B show trends over time for the prevalence of different substances in injured Canadian drivers.

There were 108 drivers of off-road vehicles (ATVs, dirt bikes, snow mobiles, etc.) that were excluded from this analysis. We report substance prevalence for these drivers in Table 5 of Appendix A.



### Discussion

In this sample of 8317 injured drivers treated in 15 trauma centres across Canada since January 2018, over half of the drivers (53.7%) tested positive for at least one impairing substance. The most common single substance detected was cannabis with about one in six drivers (17.9%) testing positive for THC, the active ingredient in cannabis. Most of the THC positive drivers had low levels (< 2 ng/mL) which do not necessarily reflect recent use of cannabis, and do not appear to be associated with increased risk of crashing.<sup>72</sup> However, one in 13 drivers (7.8%) had THC  $\geq$  2 ng/mL which usually indicates recent use of cannabis, and one in 29 drivers (3.5%) had THC ≥ 5 ng/mL which indicates recent use and is often associated with impairment. Cannabis use was more common in drivers under the age of 35 and more common in males than females (6.0% vs 3.2%). It should be noted that these estimates may change as more cases are collected and analyzed. The current state of knowledge indicates that the risk of crashing after using cannabis remains poorly defined but is lower than that for alcohol.<sup>24, 72</sup> Several recent metaanalyses concluded that cannabis increases crash risk, with estimated Odds Ratios (ORs) ranging from 1.36 to 2.66.<sup>52, 54</sup> A recent Canadian study suggests that drivers with THC levels < 5 ng/mL do not have an increased risk of crashing.<sup>72</sup> However, it is worth monitoring the prevalence of drivers with THC  $\geq$  5 ng/mL over time to analyze whether cannabis impaired driving may be an emerging problem in Canada. especially in younger drivers.

Alcohol was the second most detected impairing substance in this sample. Approximately, one in six drivers (16.1%) had been drinking (BAC > 0), and one in eight (12.3%) had BAC  $\geq$  0.08%. In this sample, alcohol was more commonly found in drivers between the ages of 19 to 34 and more common in male than female drivers (18.8% vs 10.6%). It is well known that drivers with BAC > 0.08%, especially younger drivers, have a very high crash risk<sup>6, 72, 73</sup>. These data suggest that alcohol impaired driving remains a bigger problem than drug impaired driving in Canada.

CNS stimulants (cocaine, amphetamines) were detected in one in eight injured drivers (11.8%). The highest prevalence of CNS stimulants was found in drivers between the ages of 25 to 44 with increased prevalence in males (13.5%) compared to females (8.2%). CNS depressants (including over-the-counter antihistamines) were found in approximately one in four drivers (26.5%) with a greater prevalence in females (32.2%) than males (23.7%). The highest prevalence of CNS depressants was found in drivers over the age of 55 (30.8%). These results are not surprising since sedating medication use is typically more common in older age groups. Opiates were detected in one in nine drivers (11.0%) and were detected more commonly in males (11.5%) than females (9.9%) in this sample. Cocaine, amphetamines, CNS depressants and opiates are also known to impair the psychomotor skills required for safe driving.<sup>55, 74</sup> The crash risk associated with these substances is also poorly defined but appears to be less than that associated with alcohol and in the range of that associated with cannabis.<sup>72</sup>



### **Strengths**

Our methods have several advantages. We measured drugs in blood, which, for THC and most other drugs, correlates better with impairment and/or recent use than drug levels measured in saliva or urine. Our methods quantify alcohol, THC and over 80 other impairing drugs and medications. Further, we use blood obtained shortly after the crash, in most cases within 1.5 hours, so our toxicology results closely approximate drug levels at time of crash.<sup>18</sup> This short time interval between crash and blood draw simplifies interpretation of toxicology findings. Third, the decision to obtain blood is *not* based on suspicion of drug use: blood is obtained when clinically indicated for managing the patient's injuries, based on crash mechanism and/or physical examination. This process eliminates the selection bias that would occur if drug testing was based on suspicion of drug use. Also, because this study has ethics approval for waiver of consent due to our innovative methods of anonymizing linked data, we avoid the bias that would arise if drivers who used drugs were less likely to consent for testing, as might be the case in roadside surveys. Most important, we study recent drug use in a relevant population (drivers injured in a crash).

### Limitations

There are also several limitations to this study. Because we rely on blood that was obtained for clinical purposes, we do not have control over which drivers are actually tested. As a result, our sample does not include minimally injured drivers even if they caused a crash that seriously injured another road user. It is also possible that the decision to obtain blood tests varies from hospital to hospital which may make results from different hospitals difficult to compare. Although we aim to exclude "post-crash" medications, these medications may not always be listed in ED records. In particular, we exclude ketamine from this report since it is commonly administered as part of clinical care in the prehospital setting and we suspect it is not always documented in the available medical charts. Ketamine was detected in 662 (8.0%) of injured drivers, but nearly three-quarters of these drivers (n=471; 71%) had Ketamine documented as given prior to blood draw. We are uncertain how often ketamine was actually used prior to the collision in the 191 drivers (2.3%) who tested positive for ketamine but no documentation of it being given medically. Another limitation is that our toxicology analysis is unable to measure inhalants (such as toluene). We suspect that inhalant abuse is rare but are unable to prove that this is the case. A final limitation is that we do not examine, or interview injured drivers and are unable to assess their whether drivers are actually impaired.

### Summary

Driving after cannabis use appears to be an emerging problem in Canada and may now be more common than driving after drinking alcohol. However, given the very high crash risk associated with alcohol, and the fact that most "cannabis positive" drivers had low THC levels, it can be concluded that driving after drinking remains a bigger problem in Canada. Sedating medications, opiates, and other recreational drugs were also commonly detected. Another striking feature of this study was the prevalence of polysubstance use, with approximately one in five drivers (21.8%) testing positive for more than one impairing substance. Social marketing campaigns or traffic policy designed to prevent impaired driving should continue to target alcohol as well as cannabis and other drugs and should be sensitive to the fact that many drivers use combinations of multiple impairing substances. The high prevalence of sedating medications, in multiple age ranges, suggests the need for better education on prescription practices and on use of sedating medications by drivers (including over the counter antihistamines).



## **Appendix A: Tables**

Table 1. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex	16
Table 1.1. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2018	17
Table 1.2. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2019	18
Table 1.3. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2020	19
Table 1.4. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2021	20
Table 1.5. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2022 (additional data from 2022 is pending)	21
Table 2. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances by crash characteristics	22
Table 2.1. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances b crash characteristics in 2018	by 23
Table 2.2. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances b crash characteristics in 2019	by 24
Table 2.3. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances b crash characteristics in 2020	by 25
Table 2.4. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances b crash characteristics in 2021	by 26
Table 2.5. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances b crash characteristics in 2022 (additional data from 2022 is pending)	by 27
Table 3. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region	28
Table 3.1. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region in 2018	29
Table 3.2. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region in 2019	30



Table 3.3. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region in 2020	31
Table 3.4. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region in 2021	32
Table 3.5. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region in 2022 (additional data from 2022 is pending)	33
Table 4. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in Canada	34
Table 4.1. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2018	35
Table 4.2. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2019	36
Table 4.3. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2020	37
Table 4.4. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2021	38
Table 4.5. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2022 (additional data from 2022 is pending)	39
Table 5. Off-road vehicles: Count (percent) of injured drivers involved in off-road vehicle crashes who test positive for impairing substances by age and sex	40
Table 6. Injured drivers by trauma centre: Count of injured drivers who met inclusion criteria by trauma centre emergency visit	of 41
Table 7. List of drugs included in each substance category	42



## Table 1. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex

		Age group (years)						Sex	
	National	16-18	19-24	25-34	35-44	45-54	≥55	Female	Male
Total injured drivers	8317 (100%)	297 (100%)	1091 (100%)	1891 (100%)	1407 (100%)	1242 (100%)	2389 (100%)	2724 (100%)	5593 (100%)
Alcohol									
BAC > 0	1339 (16.1%)	45 (15.2%)	258 (23.6%)	431 (22.8%)	256 (18.2%)	164 (13.2%)	185 (7.7%)	290 (10.6%)	1049 (18.8%
0 < BAC < 0.05%	217 (2.6%)	9 (3.0%)	37 (3.4%)	60 (3.2%)	41 (2.9%)	23 (1.9%)	47 (2.0%)	45 (1.7%)	172 (3.1%)
0.05% ≤ BAC < 0.08%	95 (1.1%)	7 (2.4%)	16 (1.5%)	27 (1.4%)	19 (1.4%)	13 (1.0%)	13 (0.5%)	14 (0.5%)	81 (1.4%)
BAC ≥ 0.08%	1027 (12.3%)	29 (9.8%)	205 (18.8%)	344 (18.2%)	196 (13.9%)	128 (10.3%)	125 (5.2%)	231 (8.5%)	796 (14.2%)
Cannabinoids									
COOH-THC > 0	2540 (30.5%)	121 (40.7%)	511 (46.8%)	799 (42.3%)	435 (30.9%)	278 (22.4%)	396 (16.6%)	627 (23.0%)	1913 (34.2%)
THC > 0	1491 (17.9%)	70 (23.6%)	345 (31.6%)	467 (24.7%)	241 (17.1%)	158 (12.7%)	210 (8.8%)	343 (12.6%)	1148 (20.5%)
THC ≥ 2 ng/mL	647 (7.8%)	31 (10.4%)	162 (14.8%)	204 (10.8%)	105 (7.5%)	55 (4.4%)	90 (3.8%)	149 (5.5%)	498 (8.9%)
THC ≥ 5 ng/mL	288 (3.5%)	13 (4.4%)	69 (6.3%)	99 (5.2%)	51 (3.6%)	20 (1.6%)	36 (1.5%)	64 (2.3%)	224 (4.0%)
Other substances									
CNS stimulants	978 (11.8%)	24 (8.1%)	130 (11.9%)	325 (17.2%)	245 (17.4%)	147 (11.8%)	107 (4.5%)	224 (8.2%)	754 (13.5%)
CNS depressants	2203 (26.5%)	52 (17.5%)	224 (20.5%)	446 (23.6%)	401 (28.5%)	344 (27.7%)	736 (30.8%)	878 (32.2%)	1325 (23.7%
Opioids	914 (11.0%)	21 (7.1%)	95 (8.7%)	200 (10.6%)	186 (13.2%)	143 (11.5%)	269 (11.3%)	271 (9.9%)	643 (11.5%)
Any substance	4463 (53.7%)	152 (51.2%)	656 (60.1%)	1122 (59.3%)	829 (58.9%)	615 (49.5%)	1089 (45.6%)	1357 (49.8%)	3106 (55.5%

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



### Table 1.1. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2018

Data on drivers involved in cra	shes in 2018								
		Age group (years)						Sex	
	National	16-18	19-24	25-34	35-44	45-54	≥55	Female	Male
Total injured drivers	1990 (100%)	71 (100%)	297 (100%)	430 (100%)	306 (100%)	311 (100%)	575 (100%)	631 (100%)	1359 (100%)
Alcohol									
BAC > 0	308 (15.5%)	14 (19.7%)	70 (23.6%)	95 (22.1%)	56 (18.3%)	32 (10.3%)	41 (7.1%)	61 (9.7%)	247 (18.2%)
0 < BAC < 0.05%	47 (2.4%)	2 (2.8%)	9 (3.0%)	17 (4.0%)	9 (2.9%)	2 (0.6%)	8 (1.4%)	6 (1.0%)	41 (3.0%)
0.05% ≤ BAC < 0.08%	30 (1.5%)	0 (0.0%)	7 (2.4%)	6 (1.4%)	8 (2.6%)	6 (1.9%)	3 (0.5%)	3 (0.5%)	27 (2.0%)
BAC ≥ 0.08%	231 (11.6%)	12 (16.9%)	54 (18.2%)	72 (16.7%)	39 (12.7%)	24 (7.7%)	30 (5.2%)	52 (8.2%)	179 (13.2%)
Cannabinoids									
COOH-THC > 0	532 (26.7%)	29 (40.8%)	132 (44.4%)	152 (35.3%)	79 (25.8%)	59 (19.0%)	81 (14.1%)	110 (17.4%)	422 (31.1%)
THC > 0	361 (18.1%)	21 (29.6%)	92 (31.0%)	105 (24.4%)	50 (16.3%)	45 (14.5%)	48 (8.3%)	65 (10.3%)	296 (21.8%)
THC ≥ 2 ng/mL	130 (6.5%)	9 (12.7%)	39 (13.1%)	38 (8.8%)	18 (5.9%)	10 (3.2%)	16 (2.8%)	26 (4.1%)	104 (7.7%)
THC ≥ 5 ng/mL	49 (2.5%)	3 (4.2%)	12 (4.0%)	20 (4.7%)	7 (2.3%)	2 (0.6%)	5 (0.9%)	10 (1.6%)	39 (2.9%)
Other substances									
CNS stimulants	194 (9.7%)	8 (11.3%)	31 (10.4%)	64 (14.9%)	37 (12.1%)	34 (10.9%)	20 (3.5%)	46 (7.3%)	148 (10.9%)
CNS depressants	403 (20.3%)	11 (15.5%)	36 (12.1%)	86 (20.0%)	67 (21.9%)	63 (20.3%)	140 (24.3%)	147 (23.3%)	256 (18.8%)
Opioids	168 (8.4%)	5 (7.0%)	17 (5.7%)	39 (9.1%)	29 (9.5%)	24 (7.7%)	54 (9.4%)	53 (8.4%)	115 (8.5%)
Any substance	961 (48.3%)	37 (52.1%)	170 (57.2%)	237 (55.1%)	160 (52.3%)	135 (43.4%)	222 (38.6%)	264 (41.8%)	697 (51.3%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 1.2. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2019

Data on drivers involved in cra	shes in 2019								
				Age grou	ıp (years)			Sex	
	National	16-18	19-24	25-34	35-44	45-54	≥55	Female	Male
Total injured drivers	2224 (100%)	57 (100%)	276 (100%)	513 (100%)	357 (100%)	357 (100%)	664 (100%)	703 (100%)	1521 (100%)
Alcohol									
BAC > 0	341 (15.3%)	9 (15.8%)	61 (22.1%)	113 (22.0%)	63 (17.6%)	51 (14.3%)	44 (6.6%)	68 (9.7%)	273 (17.9%)
0 < BAC < 0.05%	43 (1.9%)	2 (3.5%)	6 (2.2%)	11 (2.1%)	9 (2.5%)	7 (2.0%)	8 (1.2%)	7 (1.0%)	36 (2.4%)
0.05% ≤ BAC < 0.08%	25 (1.1%)	3 (5.3%)	5 (1.8%)	7 (1.4%)	4 (1.1%)	2 (0.6%)	4 (0.6%)	3 (0.4%)	22 (1.4%)
BAC ≥ 0.08%	273 (12.3%)	4 (7.0%)	50 (18.1%)	95 (18.5%)	50 (14.0%)	42 (11.8%)	32 (4.8%)	58 (8.3%)	215 (14.1%)
Cannabinoids									
COOH-THC > 0	753 (33.9%)	22 (38.6%)	152 (55.1%)	239 (46.6%)	108 (30.3%)	88 (24.6%)	144 (21.7%)	176 (25.0%)	577 (37.9%)
THC > 0	433 (19.5%)	8 (14.0%)	108 (39.1%)	138 (26.9%)	67 (18.8%)	48 (13.4%)	64 (9.6%)	80 (11.4%)	353 (23.2%)
THC ≥ 2 ng/mL	182 (8.2%)	5 (8.8%)	45 (16.3%)	57 (11.1%)	24 (6.7%)	17 (4.8%)	34 (5.1%)	38 (5.4%)	144 (9.5%)
THC ≥ 5 ng/mL	85 (3.8%)	2 (3.5%)	19 (6.9%)	31 (6.0%)	12 (3.4%)	5 (1.4%)	16 (2.4%)	18 (2.6%)	67 (4.4%)
Other substances									
CNS stimulants	238 (10.7%)	2 (3.5%)	35 (12.7%)	74 (14.4%)	57 (16.0%)	34 (9.5%)	36 (5.4%)	52 (7.4%)	186 (12.2%)
CNS depressants	642 (28.9%)	10 (17.5%)	80 (29.0%)	120 (23.4%)	105 (29.4%)	115 (32.2%)	212 (31.9%)	229 (32.6%)	413 (27.2%)
Opioids	257 (11.6%)	8 (14.0%)	28 (10.1%)	58 (11.3%)	40 (11.2%)	36 (10.1%)	87 (13.1%)	66 (9.4%)	191 (12.6%)
Any substance	1259 (56.6%)	30 (52.6%)	185 (67.0%)	308 (60.0%)	220 (61.6%)	191 (53.5%)	325 (48.9%)	353 (50.2%)	906 (59.6%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic

antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 1.3. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2020

Data on drivers involved in cra	shes in 2020									
				Age grou	ıp (years)			S	Sex	
	National	16-18	19-24	25-34	35-44	45-54	≥55	Female	Male	
Total injured drivers	1159 (100%)	40 (100%)	135 (100%)	274 (100%)	210 (100%)	172 (100%)	328 (100%)	409 (100%)	750 (100%)	
Alcohol										
BAC > 0	189 (16.3%)	7 (17.5%)	34 (25.2%)	60 (21.9%)	38 (18.1%)	27 (15.7%)	23 (7.0%)	48 (11.7%)	141 (18.8%)	
0 < BAC < 0.05%	41 (3.5%)	2 (5.0%)	7 (5.2%)	9 (3.3%)	7 (3.3%)	5 (2.9%)	11 (3.4%)	13 (3.2%)	28 (3.7%)	
0.05% ≤ BAC < 0.08%	10 (0.9%)	0 (0.0%)	2 (1.5%)	4 (1.5%)	1 (0.5%)	2 (1.2%)	1 (0.3%)	6 (1.5%)	4 (0.5%)	
BAC ≥ 0.08%	138 (11.9%)	5 (12.5%)	25 (18.5%)	47 (17.2%)	30 (14.3%)	20 (11.6%)	11 (3.4%)	29 (7.1%)	109 (14.5%)	
Cannabinoids										
COOH-THC > 0	363 (31.3%)	17 (42.5%)	63 (46.7%)	123 (44.9%)	68 (32.4%)	41 (23.8%)	51 (15.5%)	102 (24.9%)	261 (34.8%)	
THC > 0	192 (16.6%)	7 (17.5%)	43 (31.9%)	66 (24.1%)	34 (16.2%)	17 (9.9%)	25 (7.6%)	61 (14.9%)	131 (17.5%)	
THC ≥ 2 ng/mL	107 (9.2%)	4 (10.0%)	25 (18.5%)	37 (13.5%)	16 (7.6%)	9 (5.2%)	16 (4.9%)	30 (7.3%)	77 (10.3%)	
THC ≥ 5 ng/mL	54 (4.7%)	2 (5.0%)	11 (8.1%)	18 (6.6%)	9 (4.3%)	6 (3.5%)	8 (2.4%)	13 (3.2%)	41 (5.5%)	
Other substances										
CNS stimulants	178 (15.4%)	5 (12.5%)	19 (14.1%)	58 (21.2%)	46 (21.9%)	29 (16.9%)	21 (6.4%)	38 (9.3%)	140 (18.7%)	
CNS depressants	322 (27.8%)	9 (22.5%)	30 (22.2%)	68 (24.8%)	64 (30.5%)	48 (27.9%)	103 (31.4%)	143 (35.0%)	179 (23.9%)	
Opioids	178 (15.4%)	1 (2.5%)	15 (11.1%)	42 (15.3%)	45 (21.4%)	35 (20.3%)	40 (12.2%)	63 (15.4%)	115 (15.3%)	
Any substance	642 (55.4%)	19 (47.5%)	84 (62.2%)	170 (62.0%)	128 (61.0%)	90 (52.3%)	151 (46.0%)	215 (52.6%)	427 (56.9%)	

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic

antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 1.4. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2021

Data on drivers involved in cra	shes in 2021								
	Age group (years)					Sex			
	National	16-18	19-24	25-34	35-44	45-54	≥55	Female	Male
Total injured drivers	2376 (100%)	103 (100%)	319 (100%)	548 (100%)	426 (100%)	311 (100%)	669 (100%)	767 (100%)	1609 (100%)
Alcohol									
BAC > 0	438 (18.4%)	12 (11.7%)	80 (25.1%)	142 (25.9%)	87 (20.4%)	46 (14.8%)	71 (10.6%)	98 (12.8%)	340 (21.1%)
0 < BAC < 0.05%	79 (3.3%)	3 (2.9%)	12 (3.8%)	21 (3.8%)	15 (3.5%)	8 (2.6%)	20 (3.0%)	19 (2.5%)	60 (3.7%)
0.05% ≤ BAC < 0.08%	27 (1.1%)	4 (3.9%)	2 (0.6%)	8 (1.5%)	5 (1.2%)	3 (1.0%)	5 (0.7%)	1 (0.1%)	26 (1.6%)
BAC ≥ 0.08%	332 (14.0%)	5 (4.9%)	66 (20.7%)	113 (20.6%)	67 (15.7%)	35 (11.3%)	46 (6.9%)	78 (10.2%)	254 (15.8%)
Cannabinoids									
COOH-THC > 0	733 (30.9%)	42 (40.8%)	142 (44.5%)	222 (40.5%)	153 (35.9%)	72 (23.2%)	102 (15.2%)	196 (25.6%)	537 (33.4%)
THC > 0	417 (17.6%)	24 (23.3%)	93 (29.2%)	121 (22.1%)	78 (18.3%)	39 (12.5%)	62 (9.3%)	114 (14.9%)	303 (18.8%)
THC ≥ 2 ng/mL	191 (8.0%)	10 (9.7%)	47 (14.7%)	58 (10.6%)	39 (9.2%)	15 (4.8%)	22 (3.3%)	43 (5.6%)	148 (9.2%)
THC ≥ 5 ng/mL	81 (3.4%)	5 (4.9%)	24 (7.5%)	19 (3.5%)	21 (4.9%)	5 (1.6%)	7 (1.0%)	15 (2.0%)	66 (4.1%)
Other substances									
CNS stimulants	319 (13.4%)	7 (6.8%)	41 (12.9%)	107 (19.5%)	96 (22.5%)	43 (13.8%)	25 (3.7%)	78 (10.2%)	241 (15.0%)
CNS depressants	684 (28.8%)	18 (17.5%)	62 (19.4%)	134 (24.5%)	140 (32.9%)	97 (31.2%)	233 (34.8%)	287 (37.4%)	397 (24.7%)
Opioids	282 (11.9%)	7 (6.8%)	32 (10.0%)	53 (9.7%)	65 (15.3%)	42 (13.5%)	83 (12.4%)	79 (10.3%)	203 (12.6%)
Any substance	1326 (55.8%)	51 (49.5%)	182 (57.1%)	330 (60.2%)	273 (64.1%)	162 (52.1%)	328 (49.0%)	425 (55.4%)	901 (56.0%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic

antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 1.5. Demographics: Count (percent) of injured drivers who test positive for impairing substances by age and sex in 2022 (additional data from 2022 is pending)

Data on drivers involved in cra	shes in 2022								
	Age group (years)						Sex		
	National	16-18	19-24	25-34	35-44	45-54	≥55	Female	Male
Total injured drivers	568 (100%)	26 (100%)	64 (100%)	126 (100%)	108 (100%)	91 (100%)	153 (100%)	214 (100%)	354 (100%)
Alcohol									
BAC > 0	63 (11.1%)	3 (11.5%)	13 (20.3%)	21 (16.7%)	12 (11.1%)	8 (8.8%)	6 (3.9%)	15 (7.0%)	48 (13.6%)
0 < BAC < 0.05%	7 (1.2%)	0 (0.0%)	3 (4.7%)	2 (1.6%)	1 (0.9%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	7 (2.0%)
0.05% ≤ BAC < 0.08%	3 (0.5%)	0 (0.0%)	0 (0.0%)	2 (1.6%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	2 (0.6%)
BAC ≥ 0.08%	53 (9.3%)	3 (11.5%)	10 (15.6%)	17 (13.5%)	10 (9.3%)	7 (7.7%)	6 (3.9%)	14 (6.5%)	39 (11.0%)
Cannabinoids									
COOH-THC > 0	159 (28.0%)	11 (42.3%)	22 (34.4%)	63 (50.0%)	27 (25.0%)	18 (19.8%)	18 (11.8%)	43 (20.1%)	116 (32.8%)
THC > 0	88 (15.5%)	10 (38.5%)	9 (14.1%)	37 (29.4%)	12 (11.1%)	9 (9.9%)	11 (7.2%)	23 (10.7%)	65 (18.4%)
THC ≥ 2 ng/mL	37 (6.5%)	3 (11.5%)	6 (9.4%)	14 (11.1%)	8 (7.4%)	4 (4.4%)	2 (1.3%)	12 (5.6%)	25 (7.1%)
THC ≥ 5 ng/mL	19 (3.3%)	1 (3.8%)	3 (4.7%)	11 (8.7%)	2 (1.9%)	2 (2.2%)	0 (0.0%)	8 (3.7%)	11 (3.1%)
Other substances									
CNS stimulants	49 (8.6%)	2 (7.7%)	4 (6.2%)	22 (17.5%)	9 (8.3%)	7 (7.7%)	5 (3.3%)	10 (4.7%)	39 (11.0%)
CNS depressants	152 (26.8%)	4 (15.4%)	16 (25.0%)	38 (30.2%)	25 (23.1%)	21 (23.1%)	48 (31.4%)	72 (33.6%)	80 (22.6%)
Opioids	29 (5.1%)	0 (0.0%)	3 (4.7%)	8 (6.3%)	7 (6.5%)	6 (6.6%)	5 (3.3%)	10 (4.7%)	19 (5.4%)
Any substance	275 (48.4%)	15 (57.7%)	35 (54.7%)	77 (61.1%)	48 (44.4%)	37 (40.7%)	63 (41.2%)	100 (46.7%)	175 (49.4%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic

antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 2. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances by crash characteristics

Data on all injured drivers avail	able to date							
		Injury severity		Crasl	n time	Crash type		
	National	Treated and released	Admitted	Nighttime	Daytime	Multi-vehicle	Single-vehicle	
Total injured drivers	8317 (100%)	5227 (100%)	2963 (100%)	3098 (100%)	5065 (100%)	4935 (100%)	3379 (100%)	
Alcohol								
BAC > 0	1339 (16.1%)	703 (13.4%)	616 (20.8%)	900 (29.1%)	409 (8.1%)	382 (7.7%)	956 (28.3%)	
0 < BAC < 0.05%	217 (2.6%)	104 (2.0%)	111 (3.7%)	109 (3.5%)	106 (2.1%)	94 (1.9%)	123 (3.6%)	
0.05% ≤ BAC < 0.08%	95 (1.1%)	40 (0.8%)	54 (1.8%)	64 (2.1%)	27 (0.5%)	28 (0.6%)	67 (2.0%)	
BAC ≥ 0.08%	1027 (12.3%)	559 (10.7%)	451 (15.2%)	727 (23.5%)	276 (5.4%)	260 (5.3%)	766 (22.7%)	
Cannabinoids								
COOH-THC > 0	2540 (30.5%)	1489 (28.5%)	1008 (34.0%)	1099 (35.5%)	1394 (27.5%)	1283 (26.0%)	1256 (37.2%)	
THC > 0	1491 (17.9%)	874 (16.7%)	600 (20.2%)	664 (21.4%)	802 (15.8%)	750 (15.2%)	741 (21.9%)	
THC ≥ 2 ng/mL	647 (7.8%)	369 (7.1%)	271 (9.1%)	290 (9.4%)	346 (6.8%)	320 (6.5%)	327 (9.7%)	
THC ≥ 5 ng/mL	288 (3.5%)	177 (3.4%)	111 (3.7%)	130 (4.2%)	157 (3.1%)	140 (2.8%)	148 (4.4%)	
Other substances								
CNS stimulants	978 (11.8%)	567 (10.8%)	392 (13.2%)	448 (14.5%)	510 (10.1%)	410 (8.3%)	567 (16.8%)	
CNS depressants	2203 (26.5%)	1311 (25.1%)	857 (28.9%)	792 (25.6%)	1371 (27.1%)	1195 (24.2%)	1007 (29.8%)	
Opioids	914 (11.0%)	438 (8.4%)	425 (14.3%)	351 (11.3%)	513 (10.1%)	460 (9.3%)	454 (13.4%)	
Any substance	4463 (53.7%)	2584 (49.4%)	1803 (60.9%)	1909 (61.6%)	2458 (48.5%)	2250 (45.6%)	2211 (65.4%)	

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 2.1. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances by crash characteristics in 2018

Data on drivers involved in cras	hes in 2018							
		Injury severity		Crasl	n time	Crash type		
	National	Treated and released	Admitted	Nighttime	Daytime	Multi-vehicle	Single-vehicle	
Total injured drivers	1990 (100%)	1188 (100%)	798 (100%)	747 (100%)	1218 (100%)	1186 (100%)	804 (100%)	
Alcohol								
BAC > 0	308 (15.5%)	167 (14.1%)	141 (17.7%)	214 (28.6%)	90 (7.4%)	81 (6.8%)	227 (28.2%)	
0 < BAC < 0.05%	47 (2.4%)	22 (1.9%)	25 (3.1%)	24 (3.2%)	23 (1.9%)	22 (1.9%)	25 (3.1%)	
0.05% ≤ BAC < 0.08%	30 (1.5%)	13 (1.1%)	17 (2.1%)	19 (2.5%)	10 (0.8%)	10 (0.8%)	20 (2.5%)	
BAC ≥ 0.08%	231 (11.6%)	132 (11.1%)	99 (12.4%)	171 (22.9%)	57 (4.7%)	49 (4.1%)	182 (22.6%)	
Cannabinoids								
COOH-THC > 0	532 (26.7%)	291 (24.5%)	238 (29.8%)	234 (31.3%)	291 (23.9%)	270 (22.8%)	262 (32.6%)	
THC > 0	361 (18.1%)	199 (16.8%)	159 (19.9%)	172 (23.0%)	184 (15.1%)	179 (15.1%)	182 (22.6%)	
THC ≥ 2 ng/mL	130 (6.5%)	66 (5.6%)	63 (7.9%)	64 (8.6%)	64 (5.3%)	67 (5.6%)	63 (7.8%)	
THC ≥ 5 ng/mL	49 (2.5%)	24 (2.0%)	25 (3.1%)	25 (3.3%)	24 (2.0%)	27 (2.3%)	22 (2.7%)	
Other substances								
CNS stimulants	194 (9.7%)	122 (10.3%)	70 (8.8%)	79 (10.6%)	113 (9.3%)	95 (8.0%)	99 (12.3%)	
CNS depressants	403 (20.3%)	222 (18.7%)	180 (22.6%)	145 (19.4%)	253 (20.8%)	223 (18.8%)	180 (22.4%)	
Opioids	168 (8.4%)	84 (7.1%)	83 (10.4%)	65 (8.7%)	103 (8.5%)	93 (7.8%)	75 (9.3%)	
Any substance	961 (48.3%)	536 (45.1%)	421 (52.8%)	434 (58.1%)	515 (42.3%)	482 (40.6%)	479 (59.6%)	

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic

antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 2.2. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances by crash characteristics in 2019

		Injury s	severity	Crasl	n time	Cras	h type
	National	Treated and released	Admitted	Nighttime	Daytime	Multi-vehicle	Single-vehicle
Total injured drivers	2224 (100%)	1336 (100%)	886 (100%)	837 (100%)	1362 (100%)	1324 (100%)	898 (100%)
Alcohol							
BAC > 0	341 (15.3%)	154 (11.5%)	186 (21.0%)	236 (28.2%)	97 (7.1%)	97 (7.3%)	243 (27.1%)
0 < BAC < 0.05%	43 (1.9%)	15 (1.1%)	28 (3.2%)	20 (2.4%)	23 (1.7%)	22 (1.7%)	21 (2.3%)
0.05% ≤ BAC < 0.08%	25 (1.1%)	9 (0.7%)	16 (1.8%)	17 (2.0%)	7 (0.5%)	9 (0.7%)	16 (1.8%)
BAC ≥ 0.08%	273 (12.3%)	130 (9.7%)	142 (16.0%)	199 (23.8%)	67 (4.9%)	66 (5.0%)	206 (22.9%)
Cannabinoids							
COOH-THC > 0	753 (33.9%)	426 (31.9%)	326 (36.8%)	311 (37.2%)	433 (31.8%)	393 (29.7%)	359 (40.0%)
THC > 0	433 (19.5%)	234 (17.5%)	198 (22.3%)	176 (21.0%)	253 (18.6%)	229 (17.3%)	204 (22.7%)
THC ≥ 2 ng/mL	182 (8.2%)	106 (7.9%)	76 (8.6%)	72 (8.6%)	108 (7.9%)	94 (7.1%)	88 (9.8%)
THC ≥ 5 ng/mL	85 (3.8%)	54 (4.0%)	31 (3.5%)	38 (4.5%)	47 (3.5%)	43 (3.2%)	42 (4.7%)
Other substances							
CNS stimulants	238 (10.7%)	123 (9.2%)	114 (12.9%)	102 (12.2%)	136 (10.0%)	113 (8.5%)	124 (13.8%)
CNS depressants	642 (28.9%)	347 (26.0%)	294 (33.2%)	236 (28.2%)	399 (29.3%)	363 (27.4%)	278 (31.0%)
Opioids	257 (11.6%)	122 (9.1%)	135 (15.2%)	100 (11.9%)	156 (11.5%)	127 (9.6%)	130 (14.5%)
Any substance	1259 (56.6%)	687 (51.4%)	570 (64.3%)	514 (61.4%)	729 (53.5%)	662 (50.0%)	595 (66.3%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic

antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 2.3. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances by crash characteristics in 2020

Data on drivers involved in cras	hes in 2020						
		Injury s	severity	Crasl	n time	Cras	h type
	National	Treated and released	Admitted	Nighttime	Daytime	Multi-vehicle	Single-vehicle
Total injured drivers	1159 (100%)	758 (100%)	332 (100%)	423 (100%)	684 (100%)	688 (100%)	470 (100%)
Alcohol							
BAC > 0	189 (16.3%)	101 (13.3%)	77 (23.2%)	119 (28.1%)	60 (8.8%)	67 (9.7%)	122 (26.0%)
0 < BAC < 0.05%	41 (3.5%)	17 (2.2%)	23 (6.9%)	23 (5.4%)	16 (2.3%)	18 (2.6%)	23 (4.9%)
0.05% ≤ BAC < 0.08%	10 (0.9%)	5 (0.7%)	4 (1.2%)	6 (1.4%)	3 (0.4%)	2 (0.3%)	8 (1.7%)
BAC ≥ 0.08%	138 (11.9%)	79 (10.4%)	50 (15.1%)	90 (21.3%)	41 (6.0%)	47 (6.8%)	91 (19.4%)
Cannabinoids							
COOH-THC > 0	363 (31.3%)	213 (28.1%)	126 (38.0%)	166 (39.2%)	181 (26.5%)	177 (25.7%)	186 (39.6%)
THC > 0	192 (16.6%)	118 (15.6%)	66 (19.9%)	91 (21.5%)	92 (13.5%)	86 (12.5%)	106 (22.6%)
THC ≥ 2 ng/mL	107 (9.2%)	65 (8.6%)	38 (11.4%)	48 (11.3%)	55 (8.0%)	43 (6.2%)	64 (13.6%)
THC ≥ 5 ng/mL	54 (4.7%)	34 (4.5%)	20 (6.0%)	27 (6.4%)	26 (3.8%)	22 (3.2%)	32 (6.8%)
Other substances							
CNS stimulants	178 (15.4%)	106 (14.0%)	61 (18.4%)	92 (21.7%)	76 (11.1%)	65 (9.4%)	113 (24.0%)
CNS depressants	322 (27.8%)	215 (28.4%)	87 (26.2%)	116 (27.4%)	192 (28.1%)	165 (24.0%)	157 (33.4%)
Opioids	178 (15.4%)	83 (10.9%)	69 (20.8%)	78 (18.4%)	76 (11.1%)	91 (13.2%)	87 (18.5%)
Any substance	642 (55.4%)	394 (52.0%)	208 (62.7%)	277 (65.5%)	331 (48.4%)	315 (45.8%)	327 (69.6%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic

antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 2.4. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances by crash characteristics in 2021

		Injury s	severity	Crasl	n time	Cras	h type
	National	Treated and released	Admitted	Nighttime	Daytime	Multi-vehicle	Single-vehicle
Total injured drivers	2376 (100%)	1509 (100%)	815 (100%)	889 (100%)	1435 (100%)	1363 (100%)	1013 (100%)
Alcohol							
BAC > 0	438 (18.4%)	236 (15.6%)	194 (23.8%)	284 (31.9%)	146 (10.2%)	124 (9.1%)	314 (31.0%)
0 < BAC < 0.05%	79 (3.3%)	45 (3.0%)	33 (4.0%)	36 (4.0%)	43 (3.0%)	30 (2.2%)	49 (4.8%)
0.05% ≤ BAC < 0.08%	27 (1.1%)	12 (0.8%)	15 (1.8%)	20 (2.2%)	6 (0.4%)	6 (0.4%)	21 (2.1%)
BAC ≥ 0.08%	332 (14.0%)	179 (11.9%)	146 (17.9%)	228 (25.6%)	97 (6.8%)	88 (6.5%)	244 (24.1%)
Cannabinoids							
COOH-THC > 0	733 (30.9%)	439 (29.1%)	279 (34.2%)	323 (36.3%)	395 (27.5%)	343 (25.2%)	390 (38.5%)
THC > 0	417 (17.6%)	258 (17.1%)	154 (18.9%)	187 (21.0%)	223 (15.5%)	195 (14.3%)	222 (21.9%)
THC ≥ 2 ng/mL	191 (8.0%)	104 (6.9%)	85 (10.4%)	91 (10.2%)	97 (6.8%)	89 (6.5%)	102 (10.1%)
THC ≥ 5 ng/mL	81 (3.4%)	48 (3.2%)	33 (4.0%)	33 (3.7%)	48 (3.3%)	35 (2.6%)	46 (4.5%)
Other substances							
CNS stimulants	319 (13.4%)	186 (12.3%)	128 (15.7%)	152 (17.1%)	159 (11.1%)	116 (8.5%)	203 (20.0%)
CNS depressants	684 (28.8%)	415 (27.5%)	256 (31.4%)	239 (26.9%)	431 (30.0%)	350 (25.7%)	334 (33.0%)
Opioids	282 (11.9%)	132 (8.7%)	126 (15.5%)	100 (11.2%)	157 (10.9%)	133 (9.8%)	149 (14.7%)
Any substance	1326 (55.8%)	769 (51.0%)	527 (64.7%)	568 (63.9%)	724 (50.5%)	634 (46.5%)	692 (68.3%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic

antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 2.5. Crash characteristics: Count (percent) of injured drivers who test positive for impairing substances by crash characteristics in 2022 (additional data from 2022 is pending)

Data on drivers involved in cras	hes in 2022						
		Injury s	everity	Crasl	n time	Cras	h type
	National	Treated and released	Admitted	Nighttime	Daytime	Multi-vehicle	Single-vehicle
Total injured drivers	568 (100%)	436 (100%)	132 (100%)	202 (100%)	366 (100%)	374 (100%)	194 (100%)
Alcohol							
BAC > 0	63 (11.1%)	45 (10.3%)	18 (13.6%)	47 (23.3%)	16 (4.4%)	13 (3.5%)	50 (25.8%)
0 < BAC < 0.05%	7 (1.2%)	5 (1.1%)	2 (1.5%)	6 (3.0%)	1 (0.3%)	2 (0.5%)	5 (2.6%)
0.05% ≤ BAC < 0.08%	3 (0.5%)	1 (0.2%)	2 (1.5%)	2 (1.0%)	1 (0.3%)	1 (0.3%)	2 (1.0%)
BAC ≥ 0.08%	53 (9.3%)	39 (8.9%)	14 (10.6%)	39 (19.3%)	14 (3.8%)	10 (2.7%)	43 (22.2%)
Cannabinoids							
COOH-THC > 0	159 (28.0%)	120 (27.5%)	39 (29.5%)	65 (32.2%)	94 (25.7%)	100 (26.7%)	59 (30.4%)
THC > 0	88 (15.5%)	65 (14.9%)	23 (17.4%)	38 (18.8%)	50 (13.7%)	61 (16.3%)	27 (13.9%)
THC ≥ 2 ng/mL	37 (6.5%)	28 (6.4%)	9 (6.8%)	15 (7.4%)	22 (6.0%)	27 (7.2%)	10 (5.2%)
THC ≥ 5 ng/mL	19 (3.3%)	17 (3.9%)	2 (1.5%)	7 (3.5%)	12 (3.3%)	13 (3.5%)	6 (3.1%)
Other substances							
CNS stimulants	49 (8.6%)	30 (6.9%)	19 (14.4%)	23 (11.4%)	26 (7.1%)	21 (5.6%)	28 (14.4%)
CNS depressants	152 (26.8%)	112 (25.7%)	40 (30.3%)	56 (27.7%)	96 (26.2%)	94 (25.1%)	58 (29.9%)
Opioids	29 (5.1%)	17 (3.9%)	12 (9.1%)	8 (4.0%)	21 (5.7%)	16 (4.3%)	13 (6.7%)
Any substance	275 (48.4%)	198 (45.4%)	77 (58.3%)	116 (57.4%)	159 (43.4%)	157 (42.0%)	118 (60.8%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic

antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.

5. Refer to Table 7 for the complete list of drugs included in each substance category.

depressants, and opioids



## Table 3. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region

	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	8317 (100%)	2775 (100%)	1895 (100%)	575 (100%)	1613 (100%)	914 (100%)	545 (100%)
Alcohol							
BAC > 0	1339 (16.1%)	325 (11.7%)	297 (15.7%)	119 (20.7%)	293 (18.2%)	176 (19.3%)	129 (23.7%)
0 < BAC < 0.05%	217 (2.6%)	61 (2.2%)	30 (1.6%)	18 (3.1%)	34 (2.1%)	42 (4.6%)	32 (5.9%)
0.05% ≤ BAC < 0.08%	95 (1.1%)	25 (0.9%)	19 (1.0%)	8 (1.4%)	28 (1.7%)	13 (1.4%)	2 (0.4%)
BAC ≥ 0.08%	1027 (12.3%)	239 (8.6%)	248 (13.1%)	93 (16.2%)	231 (14.3%)	121 (13.2%)	95 (17.4%)
Cannabinoids							
COOH-THC > 0	2540 (30.5%)	741 (26.7%)	550 (29.0%)	195 (33.9%)	561 (34.8%)	240 (26.3%)	253 (46.4%)
THC > 0	1491 (17.9%)	453 (16.3%)	279 (14.7%)	123 (21.4%)	289 (17.9%)	201 (22.0%)	146 (26.8%)
THC ≥ 2 ng/mL	647 (7.8%)	175 (6.3%)	118 (6.2%)	64 (11.1%)	124 (7.7%)	79 (8.6%)	87 (16.0%)
THC ≥ 5 ng/mL	288 (3.5%)	66 (2.4%)	59 (3.1%)	34 (5.9%)	50 (3.1%)	38 (4.2%)	41 (7.5%)
Other substances							
CNS stimulants	978 (11.8%)	280 (10.1%)	239 (12.6%)	66 (11.5%)	171 (10.6%)	118 (12.9%)	104 (19.1%)
CNS depressants	2203 (26.5%)	608 (21.9%)	542 (28.6%)	177 (30.8%)	394 (24.4%)	253 (27.7%)	229 (42.0%)
Opioids	914 (11.0%)	222 (8.0%)	259 (13.7%)	77 (13.4%)	204 (12.6%)	75 (8.2%)	77 (14.1%)
Any substance	4463 (53.7%)	1262 (45.5%)	1075 (56.7%)	352 (61.2%)	868 (53.8%)	523 (57.2%)	383 (70.3%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 3.1. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region in 2018

Data on drivers involved in cras	shes in 2018						
	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	1990 (100%)	868 (100%)	507 (100%)	101 (100%)	514 (100%)		
Alcohol							
BAC > 0	308 (15.5%)	106 (12.2%)	99 (19.5%)	24 (23.8%)	79 (15.4%)		
0 < BAC < 0.05%	47 (2.4%)	20 (2.3%)	9 (1.8%)	6 (5.9%)	12 (2.3%)		
0.05% ≤ BAC < 0.08%	30 (1.5%)	12 (1.4%)	7 (1.4%)	3 (3.0%)	8 (1.6%)		
BAC ≥ 0.08%	231 (11.6%)	74 (8.5%)	83 (16.4%)	15 (14.9%)	59 (11.5%)		
Cannabinoids							
COOH-THC > 0	532 (26.7%)	205 (23.6%)	132 (26.0%)	25 (24.8%)	170 (33.1%)		
THC > 0	361 (18.1%)	142 (16.4%)	88 (17.4%)	20 (19.8%)	111 (21.6%)		
THC ≥ 2 ng/mL	130 (6.5%)	42 (4.8%)	30 (5.9%)	10 (9.9%)	48 (9.3%)		
THC ≥ 5 ng/mL	49 (2.5%)	15 (1.7%)	12 (2.4%)	3 (3.0%)	19 (3.7%)		
Other substances							
CNS stimulants	194 (9.7%)	79 (9.1%)	58 (11.4%)	8 (7.9%)	49 (9.5%)		
CNS depressants	403 (20.3%)	146 (16.8%)	122 (24.1%)	23 (22.8%)	112 (21.8%)		
Opioids	168 (8.4%)	63 (7.3%)	49 (9.7%)	6 (5.9%)	50 (9.7%)		
Any substance	961 (48.3%)	360 (41.5%)	275 (54.2%)	53 (52.5%)	273 (53.1%)		

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 3.2. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region in 2019

	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	2224 (100%)	754 (100%)	678 (100%)	157 (100%)	512 (100%)	60 (100%)	63 (100%)
Alcohol							
BAC > 0	341 (15.3%)	80 (10.6%)	116 (17.1%)	25 (15.9%)	101 (19.7%)	10 (16.7%)	9 (14.3%)
0 < BAC < 0.05%	43 (1.9%)	13 (1.7%)	15 (2.2%)	1 (0.6%)	13 (2.5%)	1 (1.7%)	0 (0.0%)
0.05% ≤ BAC < 0.08%	25 (1.1%)	5 (0.7%)	6 (0.9%)	3 (1.9%)	10 (2.0%)	0 (0.0%)	1 (1.6%)
BAC ≥ 0.08%	273 (12.3%)	62 (8.2%)	95 (14.0%)	21 (13.4%)	78 (15.2%)	9 (15.0%)	8 (12.7%)
Cannabinoids							
COOH-THC > 0	753 (33.9%)	233 (30.9%)	225 (33.2%)	71 (45.2%)	181 (35.4%)	13 (21.7%)	30 (47.6%)
THC > 0	433 (19.5%)	143 (19.0%)	120 (17.7%)	46 (29.3%)	91 (17.8%)	10 (16.7%)	23 (36.5%)
THC ≥ 2 ng/mL	182 (8.2%)	58 (7.7%)	55 (8.1%)	19 (12.1%)	31 (6.1%)	5 (8.3%)	14 (22.2%)
THC ≥ 5 ng/mL	85 (3.8%)	20 (2.7%)	29 (4.3%)	13 (8.3%)	13 (2.5%)	2 (3.3%)	8 (12.7%)
Other substances							
CNS stimulants	238 (10.7%)	75 (9.9%)	85 (12.5%)	18 (11.5%)	46 (9.0%)	7 (11.7%)	7 (11.1%)
CNS depressants	642 (28.9%)	206 (27.3%)	203 (29.9%)	52 (33.1%)	143 (27.9%)	20 (33.3%)	18 (28.6%)
Opioids	257 (11.6%)	68 (9.0%)	94 (13.9%)	25 (15.9%)	58 (11.3%)	8 (13.3%)	4 (6.3%)
Any substance	1259 (56.6%)	389 (51.6%)	413 (60.9%)	97 (61.8%)	288 (56.2%)	35 (58.3%)	37 (58.7%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 3.3. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region in 2020

	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	1159 (100%)	312 (100%)	222 (100%)	110 (100%)	132 (100%)	246 (100%)	137 (100%)
Alcohol							
BAC > 0	189 (16.3%)	45 (14.4%)	26 (11.7%)	18 (16.4%)	21 (15.9%)	42 (17.1%)	37 (27.0%)
0 < BAC < 0.05%	41 (3.5%)	9 (2.9%)	3 (1.4%)	2 (1.8%)	1 (0.8%)	20 (8.1%)	6 (4.4%)
0.05% ≤ BAC < 0.08%	10 (0.9%)	2 (0.6%)	2 (0.9%)	1 (0.9%)	1 (0.8%)	3 (1.2%)	1 (0.7%)
BAC ≥ 0.08%	138 (11.9%)	34 (10.9%)	21 (9.5%)	15 (13.6%)	19 (14.4%)	19 (7.7%)	30 (21.9%)
Cannabinoids							
COOH-THC > 0	363 (31.3%)	88 (28.2%)	54 (24.3%)	43 (39.1%)	45 (34.1%)	60 (24.4%)	73 (53.3%)
THC > 0	192 (16.6%)	36 (11.5%)	29 (13.1%)	24 (21.8%)	16 (12.1%)	41 (16.7%)	46 (33.6%)
THC ≥ 2 ng/mL	107 (9.2%)	20 (6.4%)	16 (7.2%)	15 (13.6%)	6 (4.5%)	27 (11.0%)	23 (16.8%)
THC ≥ 5 ng/mL	54 (4.7%)	10 (3.2%)	10 (4.5%)	8 (7.3%)	0 (0.0%)	16 (6.5%)	10 (7.3%)
Other substances							
CNS stimulants	178 (15.4%)	44 (14.1%)	31 (14.0%)	18 (16.4%)	20 (15.2%)	31 (12.6%)	34 (24.8%)
CNS depressants	322 (27.8%)	68 (21.8%)	77 (34.7%)	31 (28.2%)	32 (24.2%)	61 (24.8%)	53 (38.7%)
Opioids	178 (15.4%)	34 (10.9%)	40 (18.0%)	21 (19.1%)	37 (28.0%)	26 (10.6%)	20 (14.6%)
Any substance	642 (55.4%)	146 (46.8%)	134 (60.4%)	70 (63.6%)	70 (53.0%)	129 (52.4%)	93 (67.9%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 3.4. Regional variation: Count (percent) of injured drivers who test positive for impairing substances by region in 2021

	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	2376 (100%)	633 (100%)	383 (100%)	144 (100%)	455 (100%)	459 (100%)	302 (100%)
Alcohol							
BAC > 0	438 (18.4%)	83 (13.1%)	47 (12.3%)	36 (25.0%)	92 (20.2%)	102 (22.2%)	78 (25.8%)
0 < BAC < 0.05%	79 (3.3%)	18 (2.8%)	3 (0.8%)	5 (3.5%)	8 (1.8%)	20 (4.4%)	25 (8.3%)
0.05% ≤ BAC < 0.08%	27 (1.1%)	6 (0.9%)	3 (0.8%)	1 (0.7%)	9 (2.0%)	8 (1.7%)	0 (0.0%)
BAC ≥ 0.08%	332 (14.0%)	59 (9.3%)	41 (10.7%)	30 (20.8%)	75 (16.5%)	74 (16.1%)	53 (17.5%)
Cannabinoids							
COOH-THC > 0	733 (30.9%)	160 (25.3%)	102 (26.6%)	40 (27.8%)	165 (36.3%)	132 (28.8%)	134 (44.4%)
THC > 0	417 (17.6%)	86 (13.6%)	40 (10.4%)	22 (15.3%)	71 (15.6%)	128 (27.9%)	70 (23.2%)
THC ≥ 2 ng/mL	191 (8.0%)	38 (6.0%)	17 (4.4%)	13 (9.0%)	39 (8.6%)	39 (8.5%)	45 (14.9%)
THC ≥ 5 ng/mL	81 (3.4%)	14 (2.2%)	8 (2.1%)	6 (4.2%)	18 (4.0%)	17 (3.7%)	18 (6.0%)
Other substances							
CNS stimulants	319 (13.4%)	69 (10.9%)	49 (12.8%)	19 (13.2%)	56 (12.3%)	65 (14.2%)	61 (20.2%)
CNS depressants	684 (28.8%)	147 (23.2%)	110 (28.7%)	54 (37.5%)	107 (23.5%)	129 (28.1%)	137 (45.4%)
Opioids	282 (11.9%)	50 (7.9%)	67 (17.5%)	23 (16.0%)	59 (13.0%)	35 (7.6%)	48 (15.9%)
Any substance	1326 (55.8%)	280 (44.2%)	204 (53.3%)	97 (67.4%)	237 (52.1%)	283 (61.7%)	225 (74.5%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 3.5. Regional variation: Count (percent) of injured drivers who test positive forimpairing substances by region in 2022 (additional data from 2022 is pending)

	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	568 (100%)	208 (100%)	105 (100%)	63 (100%)		149 (100%)	43 (100%)
Alcohol							
BAC > 0	63 (11.1%)	11 (5.3%)	9 (8.6%)	16 (25.4%)		22 (14.8%)	5 (11.6%)
0 < BAC < 0.05%	7 (1.2%)	1 (0.5%)	0 (0.0%)	4 (6.3%)		1 (0.7%)	1 (2.3%)
0.05% ≤ BAC < 0.08%	3 (0.5%)	0 (0.0%)	1 (1.0%)	0 (0.0%)		2 (1.3%)	0 (0.0%)
BAC ≥ 0.08%	53 (9.3%)	10 (4.8%)	8 (7.6%)	12 (19.0%)		19 (12.8%)	4 (9.3%)
Cannabinoids							
COOH-THC > 0	159 (28.0%)	55 (26.4%)	37 (35.2%)	16 (25.4%)		35 (23.5%)	16 (37.2%)
THC > 0	88 (15.5%)	46 (22.1%)	2 (1.9%)	11 (17.5%)		22 (14.8%)	7 (16.3%)
THC ≥ 2 ng/mL	37 (6.5%)	17 (8.2%)	0 (0.0%)	7 (11.1%)		8 (5.4%)	5 (11.6%)
THC ≥ 5 ng/mL	19 (3.3%)	7 (3.4%)	0 (0.0%)	4 (6.3%)		3 (2.0%)	5 (11.6%)
Other substances							
CNS stimulants	49 (8.6%)	13 (6.2%)	16 (15.2%)	3 (4.8%)		15 (10.1%)	2 (4.7%)
CNS depressants	152 (26.8%)	41 (19.7%)	30 (28.6%)	17 (27.0%)		43 (28.9%)	21 (48.8%)
Opioids	29 (5.1%)	7 (3.4%)	9 (8.6%)	2 (3.2%)		6 (4.0%)	5 (11.6%)
Any substance	275 (48.4%)	87 (41.8%)	49 (46.7%)	35 (55.6%)		76 (51.0%)	28 (65.1%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 4. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in Canada

	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	8317 (100%)	2775 (100%)	1895 (100%)	575 (100%)	1613 (100%)	914 (100%)	545 (100%)
Number of substances							
1	2651 (31.9%)	783 (28.2%)	660 (34.8%)	200 (34.8%)	515 (31.9%)	308 (33.7%)	185 (33.9%)
2	1266 (15.2%)	349 (12.6%)	304 (16.0%)	104 (18.1%)	241 (14.9%)	154 (16.8%)	114 (20.9%)
3 or more	546 (6.6%)	130 (4.7%)	111 (5.9%)	48 (8.3%)	112 (6.9%)	61 (6.7%)	84 (15.4%)
Alcohol and THC							
BAC > 0 & THC > 0	407 (4.9%)	94 (3.4%)	86 (4.5%)	44 (7.7%)	80 (5.0%)	59 (6.5%)	44 (8.1%)
BAC ≥ 0.05% & THC ≥ 2 ng/mL	135 (1.6%)	32 (1.2%)	24 (1.3%)	19 (3.3%)	29 (1.8%)	18 (2.0%)	13 (2.4%)
Alcohol and other substances							
BAC > 0 & CNS stimulants	306 (3.7%)	69 (2.5%)	62 (3.3%)	24 (4.2%)	62 (3.8%)	46 (5.0%)	43 (7.9%)
BAC > 0 & CNS depressants	407 (4.9%)	87 (3.1%)	91 (4.8%)	33 (5.7%)	80 (5.0%)	55 (6.0%)	61 (11.2%)
BAC > 0 & Opioids	148 (1.8%)	27 (1.0%)	34 (1.8%)	15 (2.6%)	38 (2.4%)	18 (2.0%)	16 (2.9%)
THC and other substances							
THC > 0 & CNS stimulants	289 (3.5%)	77 (2.8%)	51 (2.7%)	31 (5.4%)	50 (3.1%)	47 (5.1%)	33 (6.1%)
THC > 0 & CNS depressants	424 (5.1%)	111 (4.0%)	73 (3.9%)	41 (7.1%)	78 (4.8%)	58 (6.3%)	63 (11.6%)
THC > 0 & Opioids	186 (2.2%)	41 (1.5%)	41 (2.2%)	17 (3.0%)	42 (2.6%)	20 (2.2%)	25 (4.6%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. The following are considered distinct substances: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 4.1. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2018

Data on drivers involved in crashes ir	n 2018						
	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	1990 (100%)	868 (100%)	507 (100%)	101 (100%)	514 (100%)		
Number of substances							
1	596 (29.9%)	224 (25.8%)	167 (32.9%)	28 (27.7%)	177 (34.4%)		
2	274 (13.8%)	102 (11.8%)	80 (15.8%)	22 (21.8%)	70 (13.6%)		
3 or more	91 (4.6%)	34 (3.9%)	28 (5.5%)	3 (3.0%)	26 (5.1%)		
Alcohol and THC							
BAC > 0 & THC > 0	103 (5.2%)	36 (4.1%)	34 (6.7%)	10 (9.9%)	23 (4.5%)		
BAC ≥ 0.05% & THC ≥ 2 ng/mL	31 (1.6%)	9 (1.0%)	9 (1.8%)	4 (4.0%)	9 (1.8%)		
Alcohol and other substances							
BAC > 0 & CNS stimulants	48 (2.4%)	13 (1.5%)	17 (3.4%)	3 (3.0%)	15 (2.9%)		
BAC > 0 & CNS depressants	75 (3.8%)	27 (3.1%)	27 (5.3%)	4 (4.0%)	17 (3.3%)		
BAC > 0 & Opioids	27 (1.4%)	9 (1.0%)	9 (1.8%)	1 (1.0%)	8 (1.6%)		
THC and other substances							
THC > 0 & CNS stimulants	63 (3.2%)	29 (3.3%)	11 (2.2%)	5 (5.0%)	18 (3.5%)		
THC > 0 & CNS depressants	82 (4.1%)	31 (3.6%)	25 (4.9%)	1 (1.0%)	25 (4.9%)		
THC > 0 & Opioids	42 (2.1%)	14 (1.6%)	12 (2.4%)	0 (0.0%)	16 (3.1%)		

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. The following are considered distinct substances: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 4.2. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2019

	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	2224 (100%)	754 (100%)	678 (100%)	157 (100%)	512 (100%)	60 (100%)	63 (100%)
Number of substances							
1	776 (34.9%)	250 (33.2%)	256 (37.8%)	49 (31.2%)	179 (35.0%)	22 (36.7%)	20 (31.7%)
2	343 (15.4%)	103 (13.7%)	115 (17.0%)	30 (19.1%)	74 (14.5%)	9 (15.0%)	12 (19.0%)
3 or more	140 (6.3%)	36 (4.8%)	42 (6.2%)	18 (11.5%)	35 (6.8%)	4 (6.7%)	5 (7.9%)
Alcohol and THC							
BAC > 0 & THC > 0	113 (5.1%)	25 (3.3%)	38 (5.6%)	15 (9.6%)	25 (4.9%)	3 (5.0%)	7 (11.1%)
BAC ≥ 0.05% & THC ≥ 2 ng/mL	26 (1.2%)	6 (0.8%)	8 (1.2%)	4 (2.5%)	4 (0.8%)	1 (1.7%)	3 (4.8%)
Alcohol and other substances							
BAC > 0 & CNS stimulants	77 (3.5%)	22 (2.9%)	26 (3.8%)	4 (2.5%)	19 (3.7%)	3 (5.0%)	3 (4.8%)
BAC > 0 & CNS depressants	114 (5.1%)	24 (3.2%)	41 (6.0%)	9 (5.7%)	32 (6.2%)	5 (8.3%)	3 (4.8%)
BAC > 0 & Opioids	44 (2.0%)	9 (1.2%)	15 (2.2%)	3 (1.9%)	15 (2.9%)	1 (1.7%)	1 (1.6%)
THC and other substances							
THC > 0 & CNS stimulants	75 (3.4%)	18 (2.4%)	24 (3.5%)	11 (7.0%)	15 (2.9%)	2 (3.3%)	5 (7.9%)
THC > 0 & CNS depressants	132 (5.9%)	40 (5.3%)	29 (4.3%)	21 (13.4%)	28 (5.5%)	4 (6.7%)	10 (15.9%)
THC > 0 & Opioids	47 (2.1%)	14 (1.9%)	11 (1.6%)	9 (5.7%)	11 (2.1%)	1 (1.7%)	1 (1.6%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. The following are considered distinct substances: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 4.3. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2020

Data on drivers involved in crashes ir		British					Atlantic	
	National	al Columbia Alberta		Saskatchewan	Ontario	Quebec	Provinces	
Total injured drivers	1159 (100%)	312 (100%)	222 (100%)	110 (100%)	132 (100%)	246 (100%)	137 (100%)	
Number of substances								
1	358 (30.9%)	86 (27.6%)	87 (39.2%)	41 (37.3%)	33 (25.0%)	78 (31.7%)	33 (24.1%)	
2	174 (15.0%)	40 (12.8%)	27 (12.2%)	19 (17.3%)	22 (16.7%)	37 (15.0%)	29 (21.2%)	
3 or more	110 (9.5%)	20 (6.4%)	20 (9.0%)	10 (9.1%)	15 (11.4%)	14 (5.7%)	31 (22.6%)	
Alcohol and THC								
BAC > 0 & THC > 0	48 (4.1%)	7 (2.2%)	6 (2.7%)	5 (4.5%)	4 (3.0%)	11 (4.5%)	15 (10.9%)	
BAC ≥ 0.05% & THC ≥ 2 ng/mL	21 (1.8%)	5 (1.6%)	3 (1.4%)	2 (1.8%)	3 (2.3%)	4 (1.6%)	4 (2.9%)	
Alcohol and other substances								
BAC > 0 & CNS stimulants	60 (5.2%)	12 (3.8%)	7 (3.2%)	7 (6.4%)	9 (6.8%)	11 (4.5%)	14 (10.2%)	
BAC > 0 & CNS depressants	59 (5.1%)	14 (4.5%)	8 (3.6%)	1 (0.9%)	5 (3.8%)	12 (4.9%)	19 (13.9%)	
BAC > 0 & Opioids	29 (2.5%)	4 (1.3%)	2 (0.9%)	4 (3.6%)	6 (4.5%)	8 (3.3%)	5 (3.6%)	
THC and other substances								
THC > 0 & CNS stimulants	53 (4.6%)	7 (2.2%)	7 (3.2%)	9 (8.2%)	5 (3.8%)	9 (3.7%)	16 (11.7%)	
THC > 0 & CNS depressants	67 (5.8%)	7 (2.2%)	10 (4.5%)	10 (9.1%)	7 (5.3%)	13 (5.3%)	20 (14.6%)	
THC > 0 & Opioids	43 (3.7%)	6 (1.9%)	11 (5.0%)	4 (3.6%)	6 (4.5%)	7 (2.8%)	9 (6.6%)	

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. The following are considered distinct substances: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 4.4. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2021

	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	2376 (100%)	633 (100%)	383 (100%)	144 (100%)	455 (100%)	459 (100%)	302 (100%)
Number of substances							
1	730 (30.7%)	162 (25.6%)	115 (30.0%)	58 (40.3%)	126 (27.7%)	158 (34.4%)	111 (36.8%)
2	410 (17.3%)	83 (13.1%)	71 (18.5%)	25 (17.4%)	75 (16.5%)	86 (18.7%)	70 (23.2%)
3 or more	186 (7.8%)	35 (5.5%)	18 (4.7%)	14 (9.7%)	36 (7.9%)	39 (8.5%)	44 (14.6%)
Alcohol and THC							
BAC > 0 & THC > 0	128 (5.4%)	19 (3.0%)	8 (2.1%)	11 (7.6%)	28 (6.2%)	41 (8.9%)	21 (7.0%)
BAC ≥ 0.05% & THC ≥ 2 ng/mL	50 (2.1%)	8 (1.3%)	4 (1.0%)	7 (4.9%)	13 (2.9%)	12 (2.6%)	6 (2.0%)
Alcohol and other substances							
BAC > 0 & CNS stimulants	108 (4.5%)	21 (3.3%)	10 (2.6%)	7 (4.9%)	19 (4.2%)	25 (5.4%)	26 (8.6%)
BAC > 0 & CNS depressants	140 (5.9%)	21 (3.3%)	13 (3.4%)	13 (9.0%)	26 (5.7%)	31 (6.8%)	36 (11.9%)
BAC > 0 & Opioids	48 (2.0%)	5 (0.8%)	8 (2.1%)	7 (4.9%)	9 (2.0%)	9 (2.0%)	10 (3.3%)
THC and other substances							
THC > 0 & CNS stimulants	81 (3.4%)	15 (2.4%)	8 (2.1%)	5 (3.5%)	12 (2.6%)	30 (6.5%)	11 (3.6%)
THC > 0 & CNS depressants	123 (5.2%)	25 (3.9%)	9 (2.3%)	7 (4.9%)	18 (4.0%)	35 (7.6%)	29 (9.6%)
THC > 0 & Opioids	52 (2.2%)	7 (1.1%)	7 (1.8%)	4 (2.8%)	9 (2.0%)	12 (2.6%)	13 (4.3%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. The following are considered distinct substances: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



### Table 4.5. Polysubstance use: Count (percent) of injured drivers who test positive for one or more types of impairing substance in 2022 (additional data from 2022 is pending)

	National	British Columbia	Alberta	Saskatchewan	Ontario	Quebec	Atlantic Provinces
Total injured drivers	568 (100%)	208 (100%)	105 (100%)	63 (100%)		149 (100%)	43 (100%)
Number of substances							
1	191 (33.6%)	61 (29.3%)	35 (33.3%)	24 (38.1%)		50 (33.6%)	21 (48.8%)
2	65 (11.4%)	21 (10.1%)	11 (10.5%)	8 (12.7%)		22 (14.8%)	3 (7.0%)
3 or more	19 (3.3%)	5 (2.4%)	3 (2.9%)	3 (4.8%)		4 (2.7%)	4 (9.3%)
Alcohol and THC							
BAC > 0 & THC > 0	15 (2.6%)	7 (3.4%)	0 (0.0%)	3 (4.8%)		4 (2.7%)	1 (2.3%)
BAC ≥ 0.05% & THC ≥ 2 ng/mL	7 (1.2%)	4 (1.9%)	0 (0.0%)	2 (3.2%)		1 (0.7%)	0 (0.0%)
Alcohol and other substances							
BAC > 0 & CNS stimulants	13 (2.3%)	1 (0.5%)	2 (1.9%)	3 (4.8%)		7 (4.7%)	0 (0.0%)
BAC > 0 & CNS depressants	19 (3.3%)	1 (0.5%)	2 (1.9%)	6 (9.5%)		7 (4.7%)	3 (7.0%)
BAC > 0 & Opioids	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
THC and other substances							
THC > 0 & CNS stimulants	17 (3.0%)	8 (3.8%)	1 (1.0%)	1 (1.6%)		6 (4.0%)	1 (2.3%)
THC > 0 & CNS depressants	20 (3.5%)	8 (3.8%)	0 (0.0%)	2 (3.2%)		6 (4.0%)	4 (9.3%)
THC > 0 & Opioids	2 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)		0 (0.0%)	2 (4.7%)

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. The following are considered distinct substances: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Refer to Table 6 for the count of injured drivers who contributed data to this table by hospital site.



## Table 5. Off-road vehicles: Count (percent) of injured drivers involved in off-road vehicle crashes who test positive for impairing substances by age and sex

Data on all injured drivers avai	lable to date						
		Age group (years)		Sex			
	National	<30	≥30	Female	Male		
Total injured drivers	108 (100%)	33 (100%)	75 (100%)	20 (100%)	88 (100%)		
Alcohol							
BAC > 0	47 (43.5%)	14 (42.4%)	33 (44.0%)	8 (40.0%)	39 (44.3%)		
0 < BAC < 0.05%	5 (4.6%)	3 (9.1%)	2 (2.7%)	1 (5.0%)	4 (4.5%)		
0.05% ≤ BAC < 0.08%	7 (6.5%)	3 (9.1%)	4 (5.3%)	1 (5.0%)	6 (6.8%)		
BAC ≥ 0.08%	35 (32.4%)	8 (24.2%)	27 (36.0%)	6 (30.0%)	29 (33.0%)		
Cannabinoids							
COOH-THC > 0	42 (38.9%)	15 (45.5%)	27 (36.0%)	4 (20.0%)	38 (43.2%)		
THC > 0	21 (19.4%)	7 (21.2%)	14 (18.7%)	2 (10.0%)	19 (21.6%)		
THC ≥ 2 ng/mL	14 (13.0%)	6 (18.2%)	8 (10.7%)	2 (10.0%)	12 (13.6%)		
THC ≥ 5 ng/mL	8 (7.4%)	6 (18.2%)	2 (2.7%)	2 (10.0%)	6 (6.8%)		
Other substances							
CNS stimulants	12 (11.1%)	2 (6.1%)	10 (13.3%)	2 (10.0%)	10 (11.4%)		
CNS depressants	37 (34.3%)	10 (30.3%)	27 (36.0%)	8 (40.0%)	29 (33.0%)		
Opioids	17 (15.7%)	7 (21.2%)	10 (13.3%)	3 (15.0%)	14 (15.9%)		
Any substance	79 (73.1%)	25 (75.8%)	54 (72.0%)	14 (70.0%)	65 (73.9%)		

Notes:

1. "CNS Stimulants" include cocaine, methamphetamine, and other amphetamines.

2. "CNS Depressants" include antihistamines, antidepressants, anticonvulsants, antipsychotics, benzodiazepines, muscle relaxants, tricyclic antidepressants, and Z-drugs

3. "Any substance" refers to detection of any one (or more) of the following: Alcohol, THC (excludes COOH-THC), CNS stimulants, CNS depressants, and opioids.

4. Drivers of off-road vehicles are excluded from all other tables and figures in this report.



# Table 6. Injured drivers by trauma centre: Count of injured drivers who met inclusion criteria by trauma centre of emergency visit

			Count of injured drivers by year				
	Date range	Total injured drivers	2018	2019	2020	2021	2022
All sites in Canada	Jan 2018 to Aug 2022	8317	1990	2224	1159	2376	568
British Columbia							
Kelowna	Jan 2018 to Jan 2022	307	78	88	49	91	<5
New Westminster	Jan 2018 to May 2022	683	206	190	83	168	36
Vancouver	Jan 2018 to Aug 2022	1503	467	397	159	310	170
Victoria	Jan 2018 to Jan 2022	282	117	79	21	64	<5
Alberta							
Calgary	May 2018 to Jan 2022	1194	334	484	104	261	11
Edmonton	Jun 2018 to Aug 2022	701	173	194	118	122	94
Saskatchewan							
Regina	Oct 2020 to May 2022	96	-	-	10	71	15
Saskatoon	Apr 2018 to Jun 2022	479	101	157	100	73	48
Ontario							
Ottawa	Mar 2018 to Dec 2021	708	207	205	45	251	-
Toronto	Feb 2018 to Sep 2021	905	307	307	87	204	-
Quebec							
Montreal	Nov 2019 to May 2022	529	-	42	139	271	77
Quebec City	Nov 2019 to Jul 2022	385	-	18	107	188	72
Atlantic provinces							
Halifax	Jun 2019 to May 2022	300	-	63	65	135	37
Saint John	May 2020 to Dec 2021	177	-	-	69	108	-
St. John's	Dec 2020 to Jan 2022	68	-	-	<5	59	6

Notes:

1. "Date range" refers to the period of time that the specified site collected data on drivers who met inclusion criteria.

2. Due to delays in toxicology testing, this table does not include all drivers who visited a participating hospital to date. Toxicology data is pending on approximately 2000 drivers from 2022.



### Table 7. List of drugs included in each substance category

Alcohol	CNS Depressants	
Cannabinoids	Anticonvulsant	Antihistamine
	Carbamazepine	Cetirizine
THC	Cyclobenzaprine	Chlorpheniramine
COOH-THC	Gabapentin	Diphenhydramine
	Lamotrigine	Doxylamine
CNS Stimulants	Phenytoin	Tripelennamine
	Topiramate	
Amphetamine	Valproic acid	Benzodiazepine
Amphetamine	Phenobarbital	Alprazolam
MDA	i nonobarbitar	Aminoclonazepam
MDA	Antidepressant	Aminoflunitrazepam
MDMA	Bupropion	Aminonitrazepam
Cassing	Citalopram	Chlordiazepoxide
Cocaine	Fluoxetine	Clonazepam
Benzoylecgonine	Hydroxybupropion	Diazepam
Cocaethylene	Mirtazapine	Etizolam
Cocaine	Norcitalopram	
	Norsertraline	Flunitrazepam Lorazepam
Methamphetamine		Midazolam
<u></u>	ODesmethylvenlafaxine Paroxetine	
Opioids		Nitrazepam
	Sertraline	Nordiazepam
Acetylmorphine	Trazodone	Oxazepam
Buprenorphine	Venlafaxine	Temazepam
Codeine	Andinanahadia	Mussia Delauser
EDDP	Antipsychotic	Muscle Relaxant
Fentanyl	Chlorpromazine	Baclofen
Hydrocodone	Clozapine	Methocarbamol
Hydromorphone	Haloperidol	<b>—</b> · · · · · · · · · · · · · · · · · · ·
Meperidine	Hydroxyrisperidone	Tricyclic Antidepressant
Methadone	Loxapine	Amitriptyline
Mitragynine	Olanzapine	Clomipramine
Morphine	Quetiapine	Desipramine
Norfentanyl	Risperidone	Doxepin
Oxycodone	Ziprasidone	Imipramine
Tramadol	Zuclopenthixol	Nortriptyline
		Trimipramine
	Z-Drug	
	Zolpidem	Dextromethorphan
	Zopiclone	



### **Appendix B: Figures**

#### Prevalence of Alcohol

Figure 1. Prevalence of alcohol use among injured drivers in Canada, by age group	46
Figure 2. Prevalence of alcohol use among injured drivers in Canada, by sex	47
Figure 3. Prevalence of alcohol use among injured drivers in Canada, by injury severity	48
Figure 4. Prevalence of alcohol use among injured drivers in Canada, by time of crash	49
Figure 5. Prevalence of alcohol use among injured drivers in Canada, by number of vehicles involved in the crash	50
Figure 6. Prevalence of cannabinoids among injured drivers in Canada, by age group	51
Figure 7. Prevalence of cannabinoids among injured drivers in Canada, by sex	52
Figure 8. Prevalence of cannabinoids among injured drivers in Canada, by injury severity	53
Figure 9. Prevalence of cannabinoids among injured drivers in Canada, by time of crash	54
Figure 10. Prevalence of cannabinoids among injured drivers in Canada, by number of vehicles involved in the crash	55
Figure 11. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by age group	56
Figure 12. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by sex	57
Figure 13. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by injury severity	58
Figure 14. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by time of crash	59
Figure 15. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by number of vehicles involved in the crash	60
Figure 16. Use of alcohol, cannabis or both among injured drivers in Canada. The area of overlap between bot circles represents drivers who tested positive for both alcohol and THC. The majority of THC positive drivers (in green) had relatively low levels compared to most of the alcohol positive drivers (in purple) who had BAC above the 0.08% legal limit.	า



Figure 17. Polysubstance use among injured drivers in Canada. The overlapping ellipses represent drivers testing positive for various combinations of impairing substances. The cannabis ellipse counts drivers who tested positive for THC. For example, 214 (2.6%) drivers tested positive for alcohol and cannabis only.

#### Figure 18. Regional variation in substance use among injured drivers in Canada

Figure 19. Quarterly prevalence of THC > 0 ng/mL among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalence calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to Table 6 for more detail).

Figure 20. Quarterly prevalence of THC  $\geq$  2 ng/mL among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to Table 6 for more detail). 65

Figure 21. Quarterly prevalence of THC  $\ge$  5 ng/mL among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to Table 6 for more detail). 66

Figure 22. Quarterly prevalence of BAC > 0 among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to Table 6 for more detail).

Figure 23. Quarterly prevalence of BAC ≥ 0.08% ng/mL among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalence calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to Table 6 for more detail).

Figure 24. Quarterly prevalence of CNS stimulants among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalence calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to Table 6 for more detail).

Figure 25. Quarterly prevalence of opioids among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to Table 6 for more detail).

67



62 63 Figure 26. Quarterly prevalence of CNS depressants among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalence calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to Table 6 for more detail).

Figure 27. Quarterly prevalence of any impairing substance among injured drivers in Canada. Any impairing substance includes alcohol, THC, CNS stimulants, CNS depressants, and opioids. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalence calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to Table 6 for more detail).






Figure 1. Prevalence of alcohol use among injured drivers in Canada, by age group






Figure 2. Prevalence of alcohol use among injured drivers in Canada, by sex






Figure 3. Prevalence of alcohol use among injured drivers in Canada, by injury severity






Figure 4. Prevalence of alcohol use among injured drivers in Canada, by time of crash






Figure 5. Prevalence of alcohol use among injured drivers in Canada, by number of vehicles involved in the crash






Figure 6. Prevalence of cannabinoids among injured drivers in Canada, by age group






Figure 7. Prevalence of cannabinoids among injured drivers in Canada, by sex






Figure 8. Prevalence of cannabinoids among injured drivers in Canada, by injury severity







Figure 9. Prevalence of cannabinoids among injured drivers in Canada, by time of crash





*Figure 10. Prevalence of cannabinoids among injured drivers in Canada, by number of vehicles involved in the crash* 






Figure 11. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by age group








Figure 12. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by sex






*Figure 13. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by injury severity* 





*Figure 14. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by time of crash* 





*Figure 15. Prevalence of CNS stimulants, CNS depressants, and opioids among injured drivers in Canada, by number of vehicles involved in the crash* 







Figure 16. Use of alcohol, cannabis or both among injured drivers in Canada. The area of overlap between both circles represents drivers who tested positive for both alcohol and THC. The majority of THC positive drivers (in green) had relatively low levels compared to most of the alcohol positive drivers (in purple) who had BAC above the 0.08% legal limit.





*Figure 17. Polysubstance use among injured drivers in Canada. The overlapping ellipses represent drivers testing positive for various combinations of impairing substances. The cannabis ellipse counts drivers who tested positive for THC. For example, 214 (2.6%) drivers tested positive for alcohol and cannabis only.* 






Figure 18. Regional variation in substance use among injured drivers in Canada






Figure 19. Quarterly prevalence of THC > 0 ng/mL among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalence calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to <u>Table 6</u> for more detail).






Figure 20. Quarterly prevalence of THC  $\ge$  2 ng/mL among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalence calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to <u>Table 6</u> for more detail).






Figure 21. Quarterly prevalence of THC  $\geq$  5 ng/mL among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalence calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to <u>Table 6</u> for more detail).






Figure 22. Quarterly prevalence of BAC > 0 among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to <u>Table 6</u> for more detail).






Figure 23. Quarterly prevalence of BAC  $\geq$  0.08% ng/mL among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to <u>Table 6</u> for more detail).






Figure 24. Quarterly prevalence of CNS stimulants among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to <u>Table 6</u> for more detail).






Figure 25. Quarterly prevalence of opioids among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to <u>Table 6</u> for more detail).






Figure 26. Quarterly prevalence of CNS depressants among injured drivers in Canada. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to <u>Table 6</u> for more detail).






Figure 27. Quarterly prevalence of any impairing substance among injured drivers in Canada. Any impairing substance includes alcohol, THC, CNS stimulants, CNS depressants, and opioids. The sample size (n) above each quarter indicates the number of injured drivers included in the denominator of the prevalnce calculation. The dashed vertical lines represent the 95% confidence interval (CI) for the prevalence estimate in each quarter. The number of hospital sites contributing data to each quarter may differ over time (refer to <u>Table 6</u> for more detail).



### References

1. Hunault CC, Bocker KB, Stellato RK, Kenemans JL, de Vries I, Meulenbelt J. Acute subjective effects after smoking joints containing up to 69 mg Delta9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacology (Berl). 2014;231(24):4723-33.

2. Karschner EL, Swortwood MJ, Hirvonen J, Goodwin RS, Bosker WM, Ramaekers JG, et al. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. Drug Testing & Analysis. 2016;8(7):682-9.

3. Smith HW, Popham RE. Blood alcohol levels in relation to driving. Canadian Medical Association Journal. 1951;65(4):325-8.

4. Borkenstein RF, Crowther RF, Shumate RP, Ziel WB, Zylman R. The role of the drinking driver in traffic accidents (the Grand Rapids Study). Blutalcohol. 1974;11 (Suppl):7-13.

5. Zador PL, Krawchuk SA, Voas RB. Alcohol-related relative risk of driver fatalities and driver involvement in fatal crashes in relation to driver age and gender: an update using 1996 data. Journal of studies on alcohol. 2000;61(3):387-95.

6. Blomberg RD, Peck RC, Moskowitz H, Burns M, Fiorentino D. The Long Beach/Fort Lauderdale relative risk study. Journal of safety research. 2009;40(4):285-92.

7. Tippetts AS, Voas RB, Fell JC, Nichols JL, Tippetts AS, Voas RB, et al. A meta-analysis of .08 BAC laws in 19 jurisdictions in the United States. Accident Analysis & Prevention. 2005;37(1):149-61.

8. Tay R. The effectiveness of enforcement and publicity campaigns on serious crashes involving young male drivers: Are drink driving and speeding similar? Accident Analysis & Prevention. 2005;37(5):922-9.

9. Tay R. Drink driving enforcement and publicity campaigns: are the policy recommendations sensitive to model specification? Accident Analysis & Prevention. 2005;37(2):259-66.

10. Rothschild ML, Mastin B, Miller TW. Reducing alcohol-impaired driving crashes through the use of social marketing. Accident Analysis & Prevention. 2006;38(6):1218-30.

11. Asbridge. The criminalization of impaired driving in Canada: Assessing the deterrent impact of Canada's first per se law. Journal of studies on alcohol. 2004;65(4):450.

12. Simpson H, Singhal D, Vanlaar W, Mayhew D. The road safety monitor: Drugs and driving. Ottawa, Ontario, Canada: Traffic Injury Research Foundation; 2006.

13. Ialomiteanu AR, Hamilton HA, Adlaf EM, Mann RE. Substance Use, Mental Health and Well Being Among Ontario Adults. Toronto, Ontario: Centre for Addictions and Mental Health; 2016.

14. Beasley E, Beirness D. Drug use by fatally injured drivers in Canada. (2000 - 2008). Ottawa, ON: Canadian Centre on Substance Abuse. 2011.

15. Beasley E, Beirness D. Drug and Alcohol use among Drivers - the 2010 BC Roadside Survey. BC Injury Prevention Conference; Vancouver2010.

16. Beirness D, Beasley E, McClafferty K. Alcohol and drug use among drivers in Ontario: Findings from the 2014 roadside survey Toronto, Ontario: Ontario Ministry of Transportation; 2015.

17. Solomon R, Clarizio M. Total Crash Deaths Involving Alcohol and/or Drugs in Canada, by Jurisdiction: 2012. London, Ontario: MADD Canada; 2016 April 19.

18. Brubacher JR, Chan H, Martz W, Schreiber W, Asbridge M, Eppler J, et al. Prevalence of alcohol and drug use in injured British Columbia drivers. BMJ Open. 2016;6(3).

19. Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, et al. Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend. 2015;154:25-37.

20. Downey LA, King R, Papafotiou K, Swann P, Ogden E, Boorman M, et al. The effects of cannabis and alcohol on simulated driving: influences of dose and experience. Accident Analysis & Prevention. 2013;50:879-86.

21. Dubois S, Mullen N, Weaver B, Bédard M. The combined effects of alcohol and cannabis on driving: Impact on crash risk. Forensic Sci Int. 2015;248:94-100.

22. Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev. 2008;40(3):926-34.



23. Grotenhermen F, Leson G, Berghaus G, Drummer OH, Krüger HP, Longo M, et al. Developing Science-Based Per Se Limits for Driving under the Influence of Cannabis (DUIC): Findings and Recommendations by an Expert Panel. Report. Washington, DC: International Association for Cannabis as Medicine; 2005 September.

24. Sewell RA, Poling J, Sofuoglu M, Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. American Journal on Addictions. 2009;18(3):185-93.

25. Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug & Alcohol Dependence. 2004;73(2):109-19.

26. Berghaus G, Scheer N, Schmidt P, editors. Effects of Cannabis on Psychomotor Skills and Driving Performance - a Metaanalysis of Experimental Studies. International Council on Alcohol Drugs and Traffic Safety (ICADTS); 1995; Adelaide, Australia.

27. Grotenhermen F, Leson G, Berghaus G, Drummer OH, Kruger HP, Longo M, et al. Developing limits for driving under cannabis. Addiction. 2007;102(12):1910-7.

28. Berghaus G, Sticht G, Grellner W, Lenz D, Naumann T, Wiesenmuller S. Meta-analysis of empirical studies concerning the effects of medicines and illegal drugs including pharmacokinetics on safe driving. 2010.

29. Vindenes V, Jordbru D, Knapskog A-B, Kvan E, Mathisrud G, Slordal L, et al. Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway. Forensic Sci Int. 2012;219(1-3):1-11.

30. Desrosiers NA, Ramaekers JG, Chauchard E, Gorelick DA, Huestis MA. Smoked cannabis' psychomotor and neurocognitive effects in occasional and frequent smokers. J Anal Toxicol. 2015;39(4):251-61.

31. Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. Biol Psychiatry. 2016;79(7):557-67.

32. Colizzi M, Bhattacharyya S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neuroscience and biobehavioral reviews. 2018;93:1-25.

33. Soar K, Mason C, Potton A, Dawkins L. Neuropsychological effects associated with recreational cocaine use. Psychopharmacology. 2012;222(4):633-43.

34. Ramaekers JG, Kuypers KPC, Bosker WM, Brookhuis KA, Veldstra JA, Simons R, et al. Effects of stimulant drugs on actual and simulated driving: perspectives from four experimental studies conducted as part of the DRUID research consortium. Psychopharmacology. 2012;222(3):413-8.

35. Wittmann M, Leland DS, Churan J, Paulus MP. Impaired time perception and motor timing in stimulant-dependent subjects. Drug & Alcohol Dependence. 2007;90(2-3):183-92.

36. Fillmore MT, Rush CR, Hays L. Acute effects of oral cocaine on inhibitory control of behavior in humans. Drug Alcohol Depend. 2002;67(2):157-67.

37. Rush CR, Baker RW, Wright K. Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis. Drug & Alcohol Dependence. 1999;55(1-2):1-12.

38. Foltin RW, Fischman MW, Pippen PA, Kelly TH. Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans. Drug & Alcohol Dependence. 1993;32(2):93-106.

39. Smith JL, Mattick RP, Jamadar SD, Iredale JM. Deficits in behavioural inhibition in substance abuse and addiction: a meta-analysis. Drug & Alcohol Dependence. 2014;145:1-33.

40. Spronk DB, van Wel JH, Ramaekers JG, Verkes RJ. Characterizing the cognitive effects of cocaine: a comprehensive review. Neurosci Biobehav Rev. 2013;37(8):1838-59.

41. Gustavsen I, Hjelmeland K, Bernard JP, Morland J. Psychomotor performance after intake of zopiclone compared with intake of ethanol: a randomized, controlled, double-blinded trial. J Clin Psychopharmacol. 2011;31(4):481-8.

42. Conen S, Theunissen EL, Van Oers ACM, Valiente R, Ramaekers JG. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. Journal of Psychopharmacology. 2011;25(11):1517-23.

43. Zacny JP, Lichtor SA. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology. 2008;196(1):105-16.

44. Leufkens TR, Vermeeren A, Smink BE, van Ruitenbeek P, Ramaekers JG, Leufkens TRM, et al. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology (Berl). 2007;191(4):951-9.

45. Wingen M, Ramaekers JG, Schmitt JA, Wingen M, Ramaekers JG, Schmitt JAJ. Driving impairment in depressed patients receiving long-term antidepressant treatment. Psychopharmacology. 2006;188(1):84-91.

46. Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf. 2006;1(1):63-71.



47. Wingen M, Bothmer J, Langer S, Ramaekers JG. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. Journal of Clinical Psychiatry. 2005;66(4):436-43.

48. Bramness JG, Skurtveit S, Morland J. Testing for benzodiazepine inebriation--relationship between benzodiazepine concentration and simple clinical tests for impairment in a sample of drugged drivers. European Journal of Clinical Pharmacology. 2003;59(8-9):593-601.

49. Hill JL, Zacny JP. Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology. 2000;152(1):31-9.

50. Hanks GW, O'Neill WM, Simpson P, Wesnes K. The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. European Journal of Clinical Pharmacology. 1995;48(6):455-60.

51. Volz HP, Sturm Y. Antidepressant drugs and psychomotor performance. A review. Neuropsychobiology. 1995;31(3):146-55.

52. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2012;344.

53. Li MC, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G. Marijuana use and motor vehicle crashes. Epidemiol Rev. 2012;34:65-72.

54. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction. 2016;111(8):1348-59.

55. Drug use and road safety: a policy brief. Geneva, Switzerland: World Health Organization; 2016.

56. Elvik R. Risk of road accident associated with the use of drugs: A systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev. 2013;60(0):254-67.

57. Hels T, Lyckegaard A, Simonsen KW, Steentoft A, Bernhoft IM. Risk of severe driver injury by driving with psychoactive substances. Accid Anal Prev. 2013;59:346-56.

58. Compton RP, Berning A. Drug and Alcohol Crash Risk. National Highway Traffic Safety Administration. Washington, D.C.; 2015. Report No.: DOT HS 812 117.

59. Beirness DJ, Beasley EE. A roadside survey of alcohol and drug use among drivers in British Columbia. Traffic Inj Prev. 2010;11(3):215-21.

60. Beirness D, Swann P, Logan BK. Drugs and driving: Detection and deterrence. Paris, France: International Transport Forum OECD; 2010.

61. Beirness D, Beasley E. An evaluation of immediate roadside prohibitions for drinking drivers in British Columbia: Findings from roadside surveys. Traffic Inj Prev. 2014;15(3):228-33.

62. Calapai F, Cardia L, Sorbara EE, Navarra M, Gangemi S, Calapai G, et al. Cannabinoids, Blood-Brain Barrier, and Brain Disposition. Pharmaceutics. 2020;12(3).

63. Robertson MB, Li A, Yuan Y, Jiang A, Gjerde H, Staples JA, et al. Correlation between oral fluid and blood THC concentration: A systematic review and discussion of policy implications. Accid Anal Prev. 2022;173:106694.
64. Brown SW, Vanlaar WGM, Robertson RD. The Alcohol and Drug Crash Problem in Canada 2016 Report.

Ottawa, Canada: The Traffic Injury Research Foundation of Canada; 2021.

65. Brunet B, Hauet T, Hebrard W, Papet Y, Mauco G, Mura P. Postmortem redistribution of THC in the pig. International journal of legal medicine. 2010;124(6):543-9.

66. Holland MG, Schwope DM, Stoppacher R, Gillen SB, Huestis MA. Postmortem redistribution of Delta9tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Forensic Sci Int. 2011;212(1-3):247-51.

67. Lemos NP, Ingle EA. Cannabinoids in postmortem toxicology. J Anal Toxicol. 2011;35(7):394-401.

68. Pounder DJ, Jones GR. Post-mortem drug redistribution--a toxicological nightmare. Forensic Sci Int. 1990;45(3):253-63.

69. Yarema MC, Becker CE. Key concepts in postmortem drug redistribution. Clin Toxicol (Phila). 2005;43(4):235-41.

70. Brubacher JR, Chan H, Erdelyi S, Asbridge M, Mann RE, Purssell RA, et al. Police documentation of drug use in injured drivers: Implications for monitoring and preventing drug-impaired driving. Accid Anal Prev. 2018.

71. Mann RE, Stoduto G, Ialomiteanu A, Asbridge M, Smart RG, Wickens CM. Self-reported collision risk associated with cannabis use and driving after cannabis use among Ontario adults. Traffic Inj Prev. 2010;11(2):115-22.



72. Brubacher JR, Chan H, Erdelyi S, Macdonald S, Asbridge M, Mann RE, et al. Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study. Addiction. 2019.

73. Peck RC, Gebers MA, Voas RB, Romano E. The relationship between blood alcohol concentration (BAC), age, and crash risk. Journal of safety research. 2008;39(3):311-9.

74. Schulze H, Schumacher M, Urmeew R, Alvarez J, Bernhoft IM, de Gier H, et al. Driving under the influence of drugs, alcohol and medicines in Europe—findings from the DRUID project. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2012.

